Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1982 1
1984 3
1987 1
1993 1
1998 1
2000 2
2001 1
2002 1
2003 1
2004 4
2005 11
2006 9
2007 13
2008 26
2009 45
2010 90
2011 144
2012 184
2013 255
2014 329
2015 370
2016 353
2017 398
2018 406
2019 404
2020 456
2021 497
2022 454
2023 444
2024 395
2025 422
2026 7

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

5,123 results

Results by year

Filters applied: . Clear all
Page 1
Effect of metformin on insulin binding to receptors in cultured human lymphocytes and cancer cells.
Pezzino V, Trischitta V, Purrello F, Vigneri R. Pezzino V, et al. Diabetologia. 1982 Aug;23(2):131-5. doi: 10.1007/BF01271174. Diabetologia. 1982. PMID: 6751898
The effect of the biguanide metformin (dimethyl-biguanide) on insulin binding in vitro to IM-9 lymphocytes and MCF-7 human breast cancer cells was studied. ...The dose-response curves indicated that the latter cell line was more sensitive to metformin, with a …
The effect of the biguanide metformin (dimethyl-biguanide) on insulin binding in vitro to IM-9 lymphocytes and MCF-7 human breast …
Drug utilization and morbidity statistics for the evaluation of drug safety in Sweden.
Wiholm BE, Westerholm B. Wiholm BE, et al. Acta Med Scand Suppl. 1984;683:107-17. doi: 10.1111/j.0954-6820.1984.tb08726.x. Acta Med Scand Suppl. 1984. PMID: 6430038
By combining sales and prescription data with ADR-reports the risk of inducing lactic acidosis was found to be significantly higher for phenformin than for metformin. Also the incidence of tardive dyskinesia from longterm use of metoclopramide was found to be much higher t …
By combining sales and prescription data with ADR-reports the risk of inducing lactic acidosis was found to be significantly higher for phen …
Metformin and insulin receptors.
Vigneri R, Gullo D, Pezzino V. Vigneri R, et al. Diabetes Care. 1984 May-Jun;7 Suppl 1:113-7. Diabetes Care. 1984. PMID: 6376023
Specific 125I-insulin binding to cultured IM-9 human lymphocytes and MCF-7 human breast cancer cells was determined after preincubation with metformin. Specific 125I-insulin binding to circulating monocytes was also evaluated in six controls, eight obese subjects, a …
Specific 125I-insulin binding to cultured IM-9 human lymphocytes and MCF-7 human breast cancer cells was determined after preincubati …
Effects of biguanides and sulfonylureas on insulin receptors in cultured cells.
Goldfine ID, Iwamoto Y, Pezzino V, Trischitta V, Purrello F, Vigneri R. Goldfine ID, et al. Diabetes Care. 1984 May-Jun;7 Suppl 1:54-8. Diabetes Care. 1984. PMID: 6734405
The effects of the two groups of oral agents on insulin receptors were studied in several types of cells in tissue culture: MCF-7 human breast cancer cells, IM-9 human lymphocytes, human fibroblasts, and H-35 rat hepatoma cells. In none of these cells did the four sulfonyl …
The effects of the two groups of oral agents on insulin receptors were studied in several types of cells in tissue culture: MCF-7 human brea …
Effects of metformin and glibenclamide on insulin receptors in fibroblasts and tumor cells in vitro.
Mountjoy KG, Finlay GJ, Holdaway IM. Mountjoy KG, et al. J Endocrinol Invest. 1987 Dec;10(6):553-7. doi: 10.1007/BF03346992. J Endocrinol Invest. 1987. PMID: 3126223
The effects of the oral hypoglycemic agents metformin and glibenclamide on receptor binding of insulin and insulin-induced receptor down-regulation were studied in cultured normal human fibroblasts, human breast tumors (cell lines MCF-7 and T-47D) and a human colon tumor ( …
The effects of the oral hypoglycemic agents metformin and glibenclamide on receptor binding of insulin and insulin-induced receptor d …
Nongenetic mouse models of non-insulin-dependent diabetes mellitus.
Luo J, Quan J, Tsai J, Hobensack CK, Sullivan C, Hector R, Reaven GM. Luo J, et al. Metabolism. 1998 Jun;47(6):663-8. doi: 10.1016/s0026-0495(98)90027-0. Metabolism. 1998. PMID: 9627363
For this purpose, insulin resistance was induced in male C57BL/6J or Institute of Cancer Research (ICR) mice by feeding diets enriched in either fructose or fat, and hyperglycemia was induced by injecting these mice with a dose of streptozotocin (STZ) that does not cause d …
For this purpose, insulin resistance was induced in male C57BL/6J or Institute of Cancer Research (ICR) mice by feeding diets enriche …
Safety of drugs commonly used to treat hypertension, dyslipidemia, and type 2 diabetes (the metabolic syndrome): part 1.
Marcus AO. Marcus AO. Diabetes Technol Ther. 2000 Spring;2(1):101-10. doi: 10.1089/152091599316801. Diabetes Technol Ther. 2000. PMID: 11467307 Review.
Among antidiabetic agents, sulfonylureas and insulin are associated with risk for severe hypoglycemia, metformin with risk for lactic acidosis, and troglitazone with risk for idiosyncratic hepatocellular injury. Similarly, widely used antihypertensive and lipid-lowering ag …
Among antidiabetic agents, sulfonylureas and insulin are associated with risk for severe hypoglycemia, metformin with risk for lactic …
Diabetes mellitus and cancer.
Czyzyk A, Szczepanik Z. Czyzyk A, et al. Eur J Intern Med. 2000 Oct;11(5):245-252. doi: 10.1016/s0953-6205(00)00106-0. Eur J Intern Med. 2000. PMID: 11025248
Although an association between diabetes and cancer was found over 100 years ago, the issue underwent different interpretations over the subsequent decades, and only modern, prospective, epidemiological cohort and case-control studies conducted in several countries have pr …
Although an association between diabetes and cancer was found over 100 years ago, the issue underwent different interpretations over …
Prevention of pancreatic cancer induction in hamsters by metformin.
Schneider MB, Matsuzaki H, Haorah J, Ulrich A, Standop J, Ding XZ, Adrian TE, Pour PM. Schneider MB, et al. Gastroenterology. 2001 Apr;120(5):1263-70. doi: 10.1053/gast.2001.23258. Gastroenterology. 2001. PMID: 11266389
METHODS: Two groups of high fat-fed hamsters were used. One group received Metformin in drinking water for life (HF+Met group), and the other group served as a control (HF group). ...CONCLUSIONS: The results lend further support on the significant role of islet cells in pa …
METHODS: Two groups of high fat-fed hamsters were used. One group received Metformin in drinking water for life (HF+Met group), and t …
Clomiphene citrate and ovulation induction.
Sovino H, Sir-Petermann T, Devoto L. Sovino H, et al. Reprod Biomed Online. 2002 May-Jun;4(3):303-10. doi: 10.1016/s1472-6483(10)61821-4. Reprod Biomed Online. 2002. PMID: 12709286
PCOS patients may become insulin resistant, a condition improved by the administration of metformin. Other adverse effects include multiple pregnancies, an increase in the rate of multiple births, ovarian hyperstimulation and unsubstantiated claims of ovarian cancer …
PCOS patients may become insulin resistant, a condition improved by the administration of metformin. Other adverse effects include mu …
Treatment of atypical endometrial hyperplasia with an insulin-sensitizing agent.
Session DR, Kalli KR, Tummon IS, Damario MA, Dumesic DA. Session DR, et al. Gynecol Endocrinol. 2003 Oct;17(5):405-7. doi: 10.1080/09513590312331290298. Gynecol Endocrinol. 2003. PMID: 14710588 Free article.
Endometrial cancer and hyperplasia have long been associated with diabetes. Hyperinsulinemia may have a direct mitogenic effect on the endometrium and may inhibit the effect of progestogen therapy. ...A 37-year-old patient presented after failed treatment of endometrial hy …
Endometrial cancer and hyperplasia have long been associated with diabetes. Hyperinsulinemia may have a direct mitogenic effect on th …
Does bitter melon contain an activator of AMP-activated kinase?
McCarty MF. McCarty MF. Med Hypotheses. 2004;63(2):340-3. doi: 10.1016/j.mehy.2004.01.041. Med Hypotheses. 2004. PMID: 15236800
Rodent studies suggest that the thus-far-uncharacterized active components of such extracts enhance the efficiency of postprandial glucose storage in muscle and liver, and likely diminish excessive hepatic glucose output, while often down-regulating serum insulin--effects compara …
Rodent studies suggest that the thus-far-uncharacterized active components of such extracts enhance the efficiency of postprandial glucose s …
Evidence for a putative relationship between type 2 diabetes and neoplasia with particular reference to breast cancer: role of hormones, growth factors and specific receptors.
Guastamacchia E, Resta F, Triggiani V, Liso A, Licchelli B, Ghiyasaldin S, Sabbà C, Tafaro E. Guastamacchia E, et al. Curr Drug Targets Immune Endocr Metabol Disord. 2004 Mar;4(1):59-66. doi: 10.2174/1568008043339965. Curr Drug Targets Immune Endocr Metabol Disord. 2004. PMID: 15032627 Review.
The issue of a possible relationship between type 2 diabetes and cancer is still debated. Such chronic diseases show a high incidence in the general population. ...Insulin resistance, hyperestrinism and the associated hyperandrogenism may play a role in the onset of some m …
The issue of a possible relationship between type 2 diabetes and cancer is still debated. Such chronic diseases show a high incidence …
Metformin-associated respiratory alkalosis.
Bryant SM, Cumpston K, Lipsky MS, Patel N, Leikin JB. Bryant SM, et al. Am J Ther. 2004 May-Jun;11(3):236-7. doi: 10.1097/00045391-200405000-00014. Am J Ther. 2004. PMID: 15133541
Metformin therapy began 3 days before, and he denied any overdose or suicidal ideation. ...He has been asymptomatic at subsequent follow-up visits. Metformin-associated lactic acidosis is a well-known phenomenon. Respiratory alkalosis may be an early adverse event i …
Metformin therapy began 3 days before, and he denied any overdose or suicidal ideation. ...He has been asymptomatic at subsequent fol …
Reversible renal insufficiency attributable to thyroid hormone withdrawal in a patient with type 2 diabetes mellitus.
Bernet VJ. Bernet VJ. Endocr Pract. 2004 Jul-Aug;10(4):339-44. doi: 10.4158/EP.10.4.339. Endocr Pract. 2004. PMID: 15760778
An increase in thyroglobulin attributable to recombinant human thyrotropin stimulation led to detection of persistent cancer, and thyroid hormone withdrawal was begun in preparation for further 131 I treatment. ...In patients with diabetes taking metformin who have …
An increase in thyroglobulin attributable to recombinant human thyrotropin stimulation led to detection of persistent cancer, and thy …
[The glitazones].
Halimi S. Halimi S. Rev Med Interne. 2005 Jan;26(1):54-7. doi: 10.1016/j.revmed.2004.09.011. Rev Med Interne. 2005. PMID: 15639326 Review. French.
The treatment of hyperglycaemia has been based on lifestyle changes, diet and physical exercise, and oral antidiabetic drugs for reducing the microangiopathic complications and the high cardiovascular risk of these patients. For decades we used sulfonylureas, metformin and …
The treatment of hyperglycaemia has been based on lifestyle changes, diet and physical exercise, and oral antidiabetic drugs for reducing th …
Possible participation of advanced glycation end products in the pathogenesis of colorectal cancer in diabetic patients.
Yamagishi S, Nakamura K, Inoue H, Kikuchi S, Takeuchi M. Yamagishi S, et al. Med Hypotheses. 2005;64(6):1208-10. doi: 10.1016/j.mehy.2005.01.015. Med Hypotheses. 2005. PMID: 15823719
Colorectal cancer is a major public health problem, being the second most common cause of cancer in developed countries. ...Is elevation of serum AGE levels a risk factor for colorectal cancer in patients with diabetes? Does treatment with metformin, w …
Colorectal cancer is a major public health problem, being the second most common cause of cancer in developed countries. ...Is …
[Molecular action of insulin-sensitizing agents].
Kacalska O, Krzyczkowska-Sendrakowska M, Milewicz T, Zabińska-Popiela M, Bereza T, Krzysiek-Maczka G, Krzysiek J. Kacalska O, et al. Endokrynol Pol. 2005 May-Jun;56(3):308-13. Endokrynol Pol. 2005. PMID: 16350724 Review. Polish.
Diabetics have a 3-4 fold relative risk of endometrial cancer. Also, several studies have demonstrated an association between insulin resistance and endometrial cancer. ...Unlike the sulfonylureas, metformin does not act primarily by increasing insulin secret …
Diabetics have a 3-4 fold relative risk of endometrial cancer. Also, several studies have demonstrated an association between insulin …
Metformin decelerates aging and development of mammary tumors in HER-2/neu transgenic mice.
Anisimov VN, Egormin PA, Bershtein LM, Zabezhinskii MA, Piskunova TS, Popovich IG, Semenchenko AV. Anisimov VN, et al. Bull Exp Biol Med. 2005 Jun;139(6):721-3. doi: 10.1007/s10517-005-0389-9. Bull Exp Biol Med. 2005. PMID: 16224592
Transgenic FVB/N female mice carrying HER-2/neu mammary cancer gene received metformin (1200 mg/liter) with drinking water 5 days a week starting from the age of 2 months until natural death. Metformin slightly reduced food consumption, but did not change wat …
Transgenic FVB/N female mice carrying HER-2/neu mammary cancer gene received metformin (1200 mg/liter) with drinking water 5 d …
Metformin and reduced risk of cancer in diabetic patients.
Evans JM, Donnelly LA, Emslie-Smith AM, Alessi DR, Morris AD. Evans JM, et al. BMJ. 2005 Jun 4;330(7503):1304-5. doi: 10.1136/bmj.38415.708634.F7. Epub 2005 Apr 22. BMJ. 2005. PMID: 15849206 Free PMC article. No abstract available.
Effect of metformin on life span and on the development of spontaneous mammary tumors in HER-2/neu transgenic mice.
Anisimov VN, Berstein LM, Egormin PA, Piskunova TS, Popovich IG, Zabezhinski MA, Kovalenko IG, Poroshina TE, Semenchenko AV, Provinciali M, Re F, Franceschi C. Anisimov VN, et al. Exp Gerontol. 2005 Aug-Sep;40(8-9):685-93. doi: 10.1016/j.exger.2005.07.007. Exp Gerontol. 2005. PMID: 16125352
Studies in mammals have led to the suggestion that hyperglycemia and hyperinsulinemia are important factors both in aging and in the development of cancer. Insulin/insulin-like growth factor 1 (IGF-1) signaling molecules that have been linked to longevity include DAF-2 and …
Studies in mammals have led to the suggestion that hyperglycemia and hyperinsulinemia are important factors both in aging and in the develop …
The phosphatidylinositol-3-kinase inhibitor PX-866 overcomes resistance to the epidermal growth factor receptor inhibitor gefitinib in A-549 human non-small cell lung cancer xenografts.
Ihle NT, Paine-Murrieta G, Berggren MI, Baker A, Tate WR, Wipf P, Abraham RT, Kirkpatrick DL, Powis G. Ihle NT, et al. Mol Cancer Ther. 2005 Sep;4(9):1349-57. doi: 10.1158/1535-7163.MCT-05-0149. Mol Cancer Ther. 2005. PMID: 16170026 Free PMC article.
Epidermal growth factor receptor (EGFR) inhibitors such as gefitinib show antitumor activity in a subset of non-small cell lung cancer (NSCLC) patients having mutated EGFR. Recent work shows that phosphatidylinositol-3-kinase (PI3-K) is coupled to the EGFR only in NSCLC ce …
Epidermal growth factor receptor (EGFR) inhibitors such as gefitinib show antitumor activity in a subset of non-small cell lung cancer …
The treatment of NAFLD.
Trappoliere M, Tuccillo C, Federico A, Di Leva A, Niosi M, D'Alessio C, Capasso R, Coppola F, Dauria M, Loguercio C. Trappoliere M, et al. Eur Rev Med Pharmacol Sci. 2005 Sep-Oct;9(5):299-304. Eur Rev Med Pharmacol Sci. 2005. PMID: 16231594 Review.
The decision of start a medical treatment is based on the documented risk of progression to cirrhosis and liver cancer, when steatohepatitis (NASH) occurs. The therapy of this syndrome requires, as obviously, some considerations on the natural history of the condition, on …
The decision of start a medical treatment is based on the documented risk of progression to cirrhosis and liver cancer, when steatohe …
Review article: the metabolic syndrome and non-alcoholic fatty liver disease.
Loria P, Lonardo A, Carulli L, Verrone AM, Ricchi M, Lombardini S, Rudilosso A, Ballestri S, Carulli N. Loria P, et al. Aliment Pharmacol Ther. 2005 Nov;22 Suppl 2:31-6. doi: 10.1111/j.1365-2036.2005.02592.x. Aliment Pharmacol Ther. 2005. PMID: 16225469 Review.
Metabolic syndrome represents a common risk factor for premature cardiovascular disease and cancer whose core cluster includes diabetes, hypertension, dyslipidaemia and obesity. The liver is a target organ in metabolic syndrome patients in which it manifests itself with no …
Metabolic syndrome represents a common risk factor for premature cardiovascular disease and cancer whose core cluster includes diabet …
Identification of potential caloric restriction mimetics by microarray profiling.
Dhahbi JM, Mote PL, Fahy GM, Spindler SR. Dhahbi JM, et al. Physiol Genomics. 2005 Nov 17;23(3):343-50. doi: 10.1152/physiolgenomics.00069.2005. Epub 2005 Sep 27. Physiol Genomics. 2005. PMID: 16189280
We have shown that CR initiated late in life begins to extend lifespan, reduce cancer as a cause of death, and reproduce approximately three-quarters of the genomic effects of LTCR in 8 wk (CR8). ...Consistent with these results, metformin has been shown to reduce …
We have shown that CR initiated late in life begins to extend lifespan, reduce cancer as a cause of death, and reproduce approximatel …
Thyrotropin suppression by metformin.
Vigersky RA, Filmore-Nassar A, Glass AR. Vigersky RA, et al. J Clin Endocrinol Metab. 2006 Jan;91(1):225-7. doi: 10.1210/jc.2005-1210. Epub 2005 Oct 11. J Clin Endocrinol Metab. 2006. PMID: 16219720
PARTICIPANTS: Four patients with chronic hypothyroidism who were placed on metformin participated in the study. INTERVENTION, MAIN OUTCOME MEASURE: Serum TSH, free T4, and free T3 levels were measured during metformin treatment. ...Should these findings be confirmed …
PARTICIPANTS: Four patients with chronic hypothyroidism who were placed on metformin participated in the study. INTERVENTION, MAIN OU …
Use of microarray biomarkers to identify longevity therapeutics.
Spindler SR. Spindler SR. Aging Cell. 2006 Feb;5(1):39-50. doi: 10.1111/j.1474-9726.2006.00194.x. Aging Cell. 2006. PMID: 16441842 Free article.
Consistent with these results, metformin reduces cancer incidence in diabetic humans and ameliorates the onset and severity of metabolic syndrome. Metformin extends the mean and maximum lifespans of female transgenic HER-2/neu mice by 8% and 13.1% in comparis …
Consistent with these results, metformin reduces cancer incidence in diabetic humans and ameliorates the onset and severity of …
Increased cancer-related mortality for patients with type 2 diabetes who use sulfonylureas or insulin.
Bowker SL, Majumdar SR, Veugelers P, Johnson JA. Bowker SL, et al. Diabetes Care. 2006 Feb;29(2):254-8. doi: 10.2337/diacare.29.02.06.dc05-1558. Diabetes Care. 2006. PMID: 16443869
After multivariate adjustment, the sulfonylurea cohort had greater cancer-related mortality compared with the metformin cohort (adjusted HR 1.3 [95% CI 1.1-1.6]; P = 0.012). Insulin use was associated with an adjusted HR of cancer-related mortality of 1.9 (95 …
After multivariate adjustment, the sulfonylurea cohort had greater cancer-related mortality compared with the metformin cohort …
Glycoprotein changes in non-insulin dependent diabetic rats: effect of N-benzoyl-D-phenylalanine and metformin.
Pari L, Ashokkumar N. Pari L, et al. Therapie. 2006 Mar-Apr;61(2):125-31. doi: 10.2515/therapie:2006022. Therapie. 2006. PMID: 16886705
In some pathological conditions, such as cancer, rheumatoid arthritis and diabetes, there is an abnormal glycosylation of acute phase serum proteins. ...Our study suggests that NBDP and metformin possess a significant beneficial effect on glycoproteins in addition t …
In some pathological conditions, such as cancer, rheumatoid arthritis and diabetes, there is an abnormal glycosylation of acute phase …
LKB1: a sweet side to Peutz-Jeghers syndrome?
Carling D. Carling D. Trends Mol Med. 2006 Apr;12(4):144-7. doi: 10.1016/j.molmed.2006.02.003. Epub 2006 Mar 10. Trends Mol Med. 2006. PMID: 16530014 Review.
The recent discovery that the tumour suppressor LKB1 is an upstream kinase in the AMP-activated protein kinase (AMPK) cascade provided a molecular link between energy metabolism and cancer. A recent study by Shaw and colleagues elucidated the role of LKB1 in type 2 diabete …
The recent discovery that the tumour suppressor LKB1 is an upstream kinase in the AMP-activated protein kinase (AMPK) cascade provided a mol …
Improvement of glycemic control, triglycerides, and HDL cholesterol levels with muraglitazar, a dual (alpha/gamma) peroxisome proliferator-activated receptor activator, in patients with type 2 diabetes inadequately controlled with metformin monotherapy: A double-blind, randomized, pioglitazone-comparative study.
Kendall DM, Rubin CJ, Mohideen P, Ledeine JM, Belder R, Gross J, Norwood P, O'Mahony M, Sall K, Sloan G, Roberts A, Fiedorek FT, DeFronzo RA. Kendall DM, et al. Diabetes Care. 2006 May;29(5):1016-23. doi: 10.2337/diacare.2951016. Diabetes Care. 2006. PMID: 16644631 Clinical Trial.
RESEARCH DESIGN AND METHODS: A double-blind, randomized, controlled trial was performed in 1,159 patients with type 2 diabetes inadequately controlled with metformin. Patients received once-daily doses of either 5 mg muraglitazar or 30 mg pioglitazone for a total of 24 wee …
RESEARCH DESIGN AND METHODS: A double-blind, randomized, controlled trial was performed in 1,159 patients with type 2 diabetes inadequately …
Obesity: new perspectives and pharmacotherapies.
Palamara KL, Mogul HR, Peterson SJ, Frishman WH. Palamara KL, et al. Cardiol Rev. 2006 Sep-Oct;14(5):238-58. doi: 10.1097/01.crd.0000233903.57946.fd. Cardiol Rev. 2006. PMID: 16924165 Review.
There is a widespread epidemic of obesity in the United States, which has been associated with an increased risk of diabetes mellitus, cancer, and cardiovascular diseases. Although lifestyle modifications and long-term dietary vigilance remain cornerstones of weight reduct …
There is a widespread epidemic of obesity in the United States, which has been associated with an increased risk of diabetes mellitus, ca …
Metformin is an AMP kinase-dependent growth inhibitor for breast cancer cells.
Zakikhani M, Dowling R, Fantus IG, Sonenberg N, Pollak M. Zakikhani M, et al. Cancer Res. 2006 Nov 1;66(21):10269-73. doi: 10.1158/0008-5472.CAN-06-1500. Epub 2006 Oct 23. Cancer Res. 2006. PMID: 17062558
Breast cancer cells can be protected against metformin-induced growth inhibition by small interfering RNA against AMP kinase. This shows that AMP kinase pathway activation by metformin, recently shown to be necessary for metformin inhibition of glucone …
Breast cancer cells can be protected against metformin-induced growth inhibition by small interfering RNA against AMP kinase. …
Protein kinase CK2 acts as a signal molecule switching between the NDPK-A/AMPK alpha1 complex and NDPK-B.
Crawford RM, Treharne KJ, Arnaud-Dabernat S, Daniel JY, Foretz M, Viollet B, Mehta A. Crawford RM, et al. FASEB J. 2007 Jan;21(1):88-98. doi: 10.1096/fj.06-6804com. Epub 2006 Nov 29. FASEB J. 2007. Retraction in: FASEB J. 2007 Oct;21(12):3398. PMID: 17135357 Retracted.
We report that when S122 on NDPK-A is phosphorylated by AMPK alpha1 in vivo, (i.e., stimulation of AMPK using either metformin or phenformin) initiating the substrate channeling mechanism, the catalytic subunit of CK2 (CK2alpha) is expelled from the complex and translocate …
We report that when S122 on NDPK-A is phosphorylated by AMPK alpha1 in vivo, (i.e., stimulation of AMPK using either metformin or phe …
Screening candidate longevity therapeutics using gene-expression arrays.
Spindler SR, Mote PL. Spindler SR, et al. Gerontology. 2007;53(5):306-21. doi: 10.1159/000103924. Epub 2007 Jun 15. Gerontology. 2007. PMID: 17570924 Review.
However, because the mice die mostly of cancer, only chemopreventives active against specific cancers can be identified by such studies. ...We describe the identification of one compound, metformin, which reproduces a subset of the gene-expression and physiological …
However, because the mice die mostly of cancer, only chemopreventives active against specific cancers can be identified by such studi …
Opinion: alternative views of AMP-activated protein kinase.
Brenman JE, Temple BR. Brenman JE, et al. Cell Biochem Biophys. 2007;47(3):321-31. doi: 10.1007/s12013-007-0005-x. Cell Biochem Biophys. 2007. PMID: 17652778 Review.
AMPK is proposed to inhibit energy consuming activity while initiating energy producing activity during energy limitation. Demonstration that metformin, a common drug for Type 2 diabetes, requires LKB1 for full therapeutic benefit has increased interest in AMPK signaling. …
AMPK is proposed to inhibit energy consuming activity while initiating energy producing activity during energy limitation. Demonstration tha …
Frequency of micronuclei in Mexicans with type 2 diabetes mellitus.
Martínez-Pérez LM, Cerda-Flores RM, Gallegos-Cabriales EC, Dávila-Rodríguez MI, Ibarra-Costilla E, Cortés-Gutiérrez EI. Martínez-Pérez LM, et al. Prague Med Rep. 2007;108(3):248-55. Prague Med Rep. 2007. PMID: 18399062
A case-control study was carried out on a sample of 15 Mexican patients (40-56 years old) with type 2 diabetes mellitus (DM2) that had developed five years and been treated with oral hypoglycemic drugs (sulfonylurea and/or metformin), with no microvascular or macrovascular …
A case-control study was carried out on a sample of 15 Mexican patients (40-56 years old) with type 2 diabetes mellitus (DM2) that had devel …
Insulin-sensitising drugs versus the combined oral contraceptive pill for hirsutism, acne and risk of diabetes, cardiovascular disease, and endometrial cancer in polycystic ovary syndrome.
Costello M, Shrestha B, Eden J, Sjoblom P, Johnson N. Costello M, et al. Cochrane Database Syst Rev. 2007 Jan 24;(1):CD005552. doi: 10.1002/14651858.CD005552.pub2. Cochrane Database Syst Rev. 2007. Update in: Cochrane Database Syst Rev. 2020 Aug 13;8:CD005552. doi: 10.1002/14651858.CD005552.pub3. PMID: 17253562 Updated.
MAIN RESULTS: Six trials were included for analysis, four of which compared metformin versus OCP (104 participants) and two of which compared OCP combined with metformin versus OCP alone (70 participants). Limited data demonstrated no evidence of difference in effec …
MAIN RESULTS: Six trials were included for analysis, four of which compared metformin versus OCP (104 participants) and two of which …
Metformin versus oral contraceptive pill in polycystic ovary syndrome: a Cochrane review.
Costello MF, Shrestha B, Eden J, Johnson NP, Sjoblom P. Costello MF, et al. Hum Reprod. 2007 May;22(5):1200-9. doi: 10.1093/humrep/dem005. Epub 2007 Jan 29. Hum Reprod. 2007. PMID: 17261574
Limited data demonstrated no evidence of a difference in effect between metformin and the OCP on hirsutism, acne or development of type 2 diabetes mellitus. There were no trials assessing diagnosis of cardiovascular disease or endometrial cancer. ...CONCLUSIONS: The …
Limited data demonstrated no evidence of a difference in effect between metformin and the OCP on hirsutism, acne or development of ty …
Systemic treatment with the antidiabetic drug metformin selectively impairs p53-deficient tumor cell growth.
Buzzai M, Jones RG, Amaravadi RK, Lum JJ, DeBerardinis RJ, Zhao F, Viollet B, Thompson CB. Buzzai M, et al. Cancer Res. 2007 Jul 15;67(14):6745-52. doi: 10.1158/0008-5472.CAN-06-4447. Cancer Res. 2007. PMID: 17638885 Free article.
The effect of the antidiabetic drug metformin on tumor growth was investigated using the paired isogenic colon cancer cell lines HCT116 p53(+/+) and HCT116 p53(-/-). ...However, the magnitude of induction was significantly lower in metformin-treated cells, as …
The effect of the antidiabetic drug metformin on tumor growth was investigated using the paired isogenic colon cancer cell lin …
Are sulphonylureas all the same? A cohort study on cardiovascular and cancer-related mortality.
Monami M, Balzi D, Lamanna C, Barchielli A, Masotti G, Buiatti E, Marchionni N, Mannucci E. Monami M, et al. Diabetes Metab Res Rev. 2007 Sep;23(6):479-84. doi: 10.1002/dmrr.736. Diabetes Metab Res Rev. 2007. PMID: 17385195

Mortality for malignancies was significantly higher in patients treated with glibenclamide after adjustment for age, sex, BMI, and insulin and metformin treatment, [OR 3.6(1.1;11.9); p < 0.05]. A higher incidence of cardiac events was associated with glibenclamide treat

…
Mortality for malignancies was significantly higher in patients treated with glibenclamide after adjustment for age, sex, BMI, and insulin a …
Insulin, insulin-like growth factors, insulin resistance, and neoplasia.
Pollack MN. Pollack MN. Am J Clin Nutr. 2007 Sep;86(3):s820-2. doi: 10.1093/ajcn/86.3.820S. Am J Clin Nutr. 2007. PMID: 18265475 Free article. Review.
An accumulating body of epidemiologic and laboratory evidence suggests that insulin and insulin-like growth factors influence both the risk and the prognosis of cancer. In this brief review, I highlight topics covered in my lecture on research directions in this field, inc …
An accumulating body of epidemiologic and laboratory evidence suggests that insulin and insulin-like growth factors influence both the risk …
A central role for neuronal adenosine 5'-monophosphate-activated protein kinase in cancer-induced anorexia.
Ropelle ER, Pauli JR, Zecchin KG, Ueno M, de Souza CT, Morari J, Faria MC, Velloso LA, Saad MJ, Carvalheira JB. Ropelle ER, et al. Endocrinology. 2007 Nov;148(11):5220-9. doi: 10.1210/en.2007-0381. Epub 2007 Aug 23. Endocrinology. 2007. PMID: 17717055
The pathogenesis of cancer anorexia is multifactorial and associated with disturbances of the central physiological mechanisms controlling food intake. ...Thus, our data indicate that hypothalamic AMPK activation presents an attractive opportunity for the treatment of c …
The pathogenesis of cancer anorexia is multifactorial and associated with disturbances of the central physiological mechanisms contro …
Metformin inhibits mammalian target of rapamycin-dependent translation initiation in breast cancer cells.
Dowling RJ, Zakikhani M, Fantus IG, Pollak M, Sonenberg N. Dowling RJ, et al. Cancer Res. 2007 Nov 15;67(22):10804-12. doi: 10.1158/0008-5472.CAN-07-2310. Cancer Res. 2007. PMID: 18006825
Recently, we showed that metformin inhibits the growth of breast cancer cells through the activation of AMPK. Here, we show that metformin inhibits translation initiation. In MCF-7 breast cancer cells, metformin treatment led to a 30% decrease i …
Recently, we showed that metformin inhibits the growth of breast cancer cells through the activation of AMPK. Here, we show th …
Effect of metformin on clastogenic and biochemical changes induced by adriamycin in Swiss albino mice.
Aleisa AM, Al-Rejaie SS, Bakheet SA, Al-Bekari AM, Al-Shabanah OA, Al-Majed A, Al-Yahya AA, Qureshi S. Aleisa AM, et al. Mutat Res. 2007 Dec 1;634(1-2):93-100. doi: 10.1016/j.mrgentox.2007.06.005. Epub 2007 Jun 27. Mutat Res. 2007. PMID: 17693128
Hyperglycemia is commonly observed in a wide variety of diseases, including cancer. Although, therapy against glycemic control, is used in all these diseases, the diabetic cancer patients are on additional therapy with anticancer drugs. ...The exact mechanism of act …
Hyperglycemia is commonly observed in a wide variety of diseases, including cancer. Although, therapy against glycemic control, is us …
Impaired expression and function of breast cancer resistance protein (Bcrp) in brain cortex of streptozocin-induced diabetic rats.
Liu YC, Liu HY, Yang HW, Wen T, Shang Y, Liu XD, Xie L, Wang GJ. Liu YC, et al. Biochem Pharmacol. 2007 Dec 15;74(12):1766-72. doi: 10.1016/j.bcp.2007.08.021. Epub 2007 Aug 21. Biochem Pharmacol. 2007. PMID: 17915193
The aim of this study was to investigate whether diabetes mellitus (DM) affected breast cancer resistance protein (Bcrp) function and expression in rat brain. 5-week and 8-week diabetic rats were induced by streptozocin (STZ). ...Insulin treatment may attenuate the impairm …
The aim of this study was to investigate whether diabetes mellitus (DM) affected breast cancer resistance protein (Bcrp) function and …
BRCA1 and acetyl-CoA carboxylase: the metabolic syndrome of breast cancer.
Brunet J, Vazquez-Martin A, Colomer R, Graña-Suarez B, Martin-Castillo B, Menendez JA. Brunet J, et al. Mol Carcinog. 2008 Feb;47(2):157-63. doi: 10.1002/mc.20364. Mol Carcinog. 2008. PMID: 17620310
Breast cancer-associated mutations affecting the highly-conserved C-terminal BRCT domains of the tumor suppressor gene breast cancer susceptibility gene 1 (BRCA1) fully disrupt the ability of BRCA1 to interact with acetyl coenzyme A carboxylase alpha (ACCA), the rat …
Breast cancer-associated mutations affecting the highly-conserved C-terminal BRCT domains of the tumor suppressor gene breast canc …
Sitagliptin: new drug. Type 2 diabetes: limited efficacy, too many unknown risks.
[No authors listed] [No authors listed] Prescrire Int. 2008 Feb;17(93):12-5. Prescrire Int. 2008. PMID: 18354861
(1) Many drugs are available for the treatment of type 2 diabetes, but only metformin and glibenclamide have a proven impact on morbidity and mortality outcomes (only morbidity in the case of glibenclamide). If monotherapy with one of these drugs is inadequately effective, …
(1) Many drugs are available for the treatment of type 2 diabetes, but only metformin and glibenclamide have a proven impact on morbi …
Update on diabetes mellitus: prevention, treatment, and association with oral diseases.
Skamagas M, Breen TL, LeRoith D. Skamagas M, et al. Oral Dis. 2008 Mar;14(2):105-14. doi: 10.1111/j.1601-0825.2007.01425.x. Oral Dis. 2008. PMID: 18302671 Review.
For individuals who do not achieve glycemic control with lifestyle modification, there are newer medication classes that assist with weight loss, more physiologic insulins with convenient delivery systems, and old standbys like metformin and thiazolidinediones. Glycemic co …
For individuals who do not achieve glycemic control with lifestyle modification, there are newer medication classes that assist with weight …
Effectiveness of assisted reproductive technology (ART).
Myers ER, McCrory DC, Mills AA, Price TM, Swamy GK, Tantibhedhyangkul J, Wu JM, Matchar DB. Myers ER, et al. Evid Rep Technol Assess (Full Rep). 2008 May;(167):1-195. Evid Rep Technol Assess (Full Rep). 2008. PMID: 18620469 Free PMC article. Review.
Interventions for which there was sufficient evidence to demonstrate improved pregnancy or live birth rates included: (a) administration of clomiphene citrate in women with polycystic ovarian syndrome, (b) metformin plus clomiphene in women who fail to respond to clomiphen …
Interventions for which there was sufficient evidence to demonstrate improved pregnancy or live birth rates included: (a) administration of …
Important role of the LKB1-AMPK pathway in suppressing tumorigenesis in PTEN-deficient mice.
Huang X, Wullschleger S, Shpiro N, McGuire VA, Sakamoto K, Woods YL, McBurnie W, Fleming S, Alessi DR. Huang X, et al. Biochem J. 2008 Jun 1;412(2):211-21. doi: 10.1042/BJ20080557. Biochem J. 2008. PMID: 18387000
In contrast, activating the AMPK pathway by administration of metformin, phenformin or A-769662 to PTEN(+/-) mice significantly delayed tumour onset. ...Our findings highlight, using an animal model relevant to understanding human cancer, the vital role that the LKB …
In contrast, activating the AMPK pathway by administration of metformin, phenformin or A-769662 to PTEN(+/-) mice significantly delay …
Effects of chronic hyperinsulinemia in insulin-resistant patients.
Muntoni S, Muntoni S, Draznin B. Muntoni S, et al. Curr Diab Rep. 2008 Jun;8(3):233-8. doi: 10.1007/s11892-008-0040-z. Curr Diab Rep. 2008. PMID: 18625122 Review.
Downregulation of the antiatherogenic pathway and maintained activity of the proatherogenic and cancerogenic pathways lead to atherosclerosis and cancer. Exogenous insulin added to "compensatory" hyperinsulinemia might worsen the primary end points, resulting in potential …
Downregulation of the antiatherogenic pathway and maintained activity of the proatherogenic and cancerogenic pathways lead to atherosclerosi …
[Non-alcoholic fatty liver disease--new view].
Raszeja-Wyszomirska J, Lawniczak M, Marlicz W, Miezyńska-Kurtycz J, Milkiewicz P. Raszeja-Wyszomirska J, et al. Pol Merkur Lekarski. 2008 Jun;24(144):568-71. Pol Merkur Lekarski. 2008. PMID: 18702346 Review. Polish.
Non-alcoholic fatty liver disease (NAFLD) covers a wide spectrum of liver pathology--from steatosis alone, through the necroinflammatory disorder of non-alcoholic steatohepatitis (NASH) to cirrhosis and liver cancer. NAFLD/NASH is mostly related with visceral adiposity, ob …
Non-alcoholic fatty liver disease (NAFLD) covers a wide spectrum of liver pathology--from steatosis alone, through the necroinflammatory dis …
The antidiabetic drug metformin exerts an antitumoral effect in vitro and in vivo through a decrease of cyclin D1 level.
Ben Sahra I, Laurent K, Loubat A, Giorgetti-Peraldi S, Colosetti P, Auberger P, Tanti JF, Le Marchand-Brustel Y, Bost F. Ben Sahra I, et al. Oncogene. 2008 Jun 5;27(25):3576-86. doi: 10.1038/sj.onc.1211024. Epub 2008 Jan 21. Oncogene. 2008. PMID: 18212742
Recent studies suggest that metformin may reduce the risk of cancer, but its mode of action in cancer remains not elucidated. We investigated the effect of metformin on human prostate cancer cell proliferation in vitro and in vivo. Metformin …
Recent studies suggest that metformin may reduce the risk of cancer, but its mode of action in cancer remains not eluci …
Targeting AMPK: a new therapeutic opportunity in breast cancer.
Hadad SM, Fleming S, Thompson AM. Hadad SM, et al. Crit Rev Oncol Hematol. 2008 Jul;67(1):1-7. doi: 10.1016/j.critrevonc.2008.01.007. Epub 2008 Mar 14. Crit Rev Oncol Hematol. 2008. PMID: 18343152 Review.
BACKGROUND: This paper reviews the mammalian Target Of Rapamycin (mTOR) pathway dysregulation in breast cancer, and the current evidence targeting this pathway directly or through activation of AMP-activated protein kinase (AMPK) as an additional therapeutic opportunity fo …
BACKGROUND: This paper reviews the mammalian Target Of Rapamycin (mTOR) pathway dysregulation in breast cancer, and the current evide …
In vitro metformin anti-neoplastic activity in epithelial ovarian cancer.
Gotlieb WH, Saumet J, Beauchamp MC, Gu J, Lau S, Pollak MN, Bruchim I. Gotlieb WH, et al. Gynecol Oncol. 2008 Aug;110(2):246-50. doi: 10.1016/j.ygyno.2008.04.008. Epub 2008 May 21. Gynecol Oncol. 2008. PMID: 18495226
OBJECTIVE: Metformin, a commonly used drug in the treatment of type II diabetes, may reduce cancer risk and improve cancer prognosis. ...CONCLUSION: Metformin significantly inhibits the growth of ovarian cancer cell lines and potentiates cisplat …
OBJECTIVE: Metformin, a commonly used drug in the treatment of type II diabetes, may reduce cancer risk and improve cancer …
Metformin attenuates the stimulatory effect of a high-energy diet on in vivo LLC1 carcinoma growth.
Algire C, Zakikhani M, Blouin MJ, Shuai JH, Pollak M. Algire C, et al. Endocr Relat Cancer. 2008 Sep;15(3):833-9. doi: 10.1677/ERC-08-0038. Epub 2008 May 9. Endocr Relat Cancer. 2008. PMID: 18469156
Forty-eight male mice were randomized into four groups: control diet, control diet+metformin, high-energy diet, or high-energy diet+metformin. Following 8 weeks on the experimental diets, selected groups received metformin in their drinking water. ...These ex …
Forty-eight male mice were randomized into four groups: control diet, control diet+metformin, high-energy diet, or high-energy diet+ …
Cancer and aging: more puzzles, more promises?
Blagosklonny MV, Campisi J. Blagosklonny MV, et al. Cell Cycle. 2008 Sep 1;7(17):2615-8. doi: 10.4161/cc.7.17.6626. Epub 2008 Sep 16. Cell Cycle. 2008. PMID: 18719390 Free article.
In this issue of Cell Cycle, a new paper shows that metformin, an oral antidiabetic drug that activates AMP-activated protein kinase, prolongs both mean and maximal life span and prevents reproductive aging of female mice. Unexpectedly, metformin did not decrease th …
In this issue of Cell Cycle, a new paper shows that metformin, an oral antidiabetic drug that activates AMP-activated protein kinase, …
Metformin slows down aging and extends life span of female SHR mice.
Anisimov VN, Berstein LM, Egormin PA, Piskunova TS, Popovich IG, Zabezhinski MA, Tyndyk ML, Yurova MV, Kovalenko IG, Poroshina TE, Semenchenko AV. Anisimov VN, et al. Cell Cycle. 2008 Sep 1;7(17):2769-73. doi: 10.4161/cc.7.17.6625. Epub 2008 Sep 11. Cell Cycle. 2008. PMID: 18728386
On the other side, treatment with metformin failed influence blood estradiol concentration and spontaneous tumor incidence in female SHR mice. Thus, antidiabetic biguanide metformin dramatically extends life span, even without cancer prevention in this model. …
On the other side, treatment with metformin failed influence blood estradiol concentration and spontaneous tumor incidence in female …
Genetic variants of organic cation transporter 2 (OCT2) significantly reduce metformin uptake in oocytes.
Song IS, Shin HJ, Shin JG. Song IS, et al. Xenobiotica. 2008 Sep;38(9):1252-62. doi: 10.1080/00498250802130039. Xenobiotica. 2008. PMID: 18728938
The basolateral-to-apical transport of metformin was inhibited by phenoxybenzamine, an inhibitor of OCTs, but not by cyclosporine A, MK571, or fumitremorgin C, which are inhibitors of P-glycoprotein, multidrug resistance proteins (MRPs), and breast cancer resistance …
The basolateral-to-apical transport of metformin was inhibited by phenoxybenzamine, an inhibitor of OCTs, but not by cyclosporine A, …
A gene signature-based approach identifies mTOR as a regulator of p73.
Rosenbluth JM, Mays DJ, Pino MF, Tang LJ, Pietenpol JA. Rosenbluth JM, et al. Mol Cell Biol. 2008 Oct;28(19):5951-64. doi: 10.1128/MCB.00305-08. Epub 2008 Aug 4. Mol Cell Biol. 2008. PMID: 18678646 Free PMC article.
Of the pharmaceutical agents identified, there was enrichment for direct or indirect inhibitors of mammalian Target of Rapamycin (mTOR) signaling. Treatment of both primary cells and cancer cell lines with rapamycin, metformin, and pyrvinium resulted in an increase …
Of the pharmaceutical agents identified, there was enrichment for direct or indirect inhibitors of mammalian Target of Rapamycin (mTOR) sign …
AMP-activated protein kinase: structure and regulation.
Sanz P. Sanz P. Curr Protein Pept Sci. 2008 Oct;9(5):478-92. doi: 10.2174/138920308785915254. Curr Protein Pept Sci. 2008. PMID: 18855699 Free article. Review.
As a result, it has become a target for the development of new drugs for the treatment of type II diabetes, obesity or even cancer. In fact, it has been recently reported that drugs used in the treatment of diabetes, such as metformin and thiazolidinediones (TZDs), …
As a result, it has become a target for the development of new drugs for the treatment of type II diabetes, obesity or even cancer. I …
The effects of adiponectin and metformin on prostate and colon neoplasia involve activation of AMP-activated protein kinase.
Zakikhani M, Dowling RJ, Sonenberg N, Pollak MN. Zakikhani M, et al. Cancer Prev Res (Phila). 2008 Oct;1(5):369-75. doi: 10.1158/1940-6207.CAPR-08-0081. Cancer Prev Res (Phila). 2008. PMID: 19138981
Population studies provide evidence that obesity and insulin resistance are associated not only with elevated serum insulin levels and reduced serum adiponectin levels but also with increased risk of aggressive prostate and colon cancer. We show here that adiponectin activ …
Population studies provide evidence that obesity and insulin resistance are associated not only with elevated serum insulin levels and reduc …
Metformin suppresses intestinal polyp growth in ApcMin/+ mice.
Tomimoto A, Endo H, Sugiyama M, Fujisawa T, Hosono K, Takahashi H, Nakajima N, Nagashima Y, Wada K, Nakagama H, Nakajima A. Tomimoto A, et al. Cancer Sci. 2008 Nov;99(11):2136-41. doi: 10.1111/j.1349-7006.2008.00933.x. Epub 2008 Sep 18. Cancer Sci. 2008. PMID: 18803638 Free PMC article.
Metformin is a biguanide derivative that is widely used in the treatment of diabetes mellitus. ...Metformin suppressed the polyp growth in Apc(Min/+) mice, suggesting that it may be a novel candidate as a chemopreventive agent for colorectal cancer....
Metformin is a biguanide derivative that is widely used in the treatment of diabetes mellitus. ...Metformin suppressed the pol …
Insulin and insulin-like growth factor signalling in neoplasia.
Pollak M. Pollak M. Nat Rev Cancer. 2008 Dec;8(12):915-28. doi: 10.1038/nrc2536. Nat Rev Cancer. 2008. PMID: 19029956 Review.
Epidermiological, clinical and laboratory research methods are being used to investigate novel cancer prevention and treatment strategies related to insulin and IGF signalling. Pharmacological strategies under study include the use of novel receptor-specific antibodies, re …
Epidermiological, clinical and laboratory research methods are being used to investigate novel cancer prevention and treatment strate …
Cell cycle arrest in Metformin treated breast cancer cells involves activation of AMPK, downregulation of cyclin D1, and requires p27Kip1 or p21Cip1.
Zhuang Y, Miskimins WK. Zhuang Y, et al. J Mol Signal. 2008 Dec 1;3:18. doi: 10.1186/1750-2187-3-18. J Mol Signal. 2008. PMID: 19046439 Free PMC article.
BACKGROUND: The antihyperglycemic drug metformin may have beneficial effects on the prevention and treatment of cancer. Metformin is known to activate AMP-activated protein kinase (AMPK). ...RESULTS: In this study, metformin was found to inhibit prolif …
BACKGROUND: The antihyperglycemic drug metformin may have beneficial effects on the prevention and treatment of cancer. Met …
Insulin-lowering effects of metformin in women with early breast cancer.
Goodwin PJ, Pritchard KI, Ennis M, Clemons M, Graham M, Fantus IG. Goodwin PJ, et al. Clin Breast Cancer. 2008 Dec;8(6):501-5. doi: 10.3816/CBC.2008.n.060. Clin Breast Cancer. 2008. PMID: 19073504 Clinical Trial.
If metformin lowers insulin levels in women with breast cancer, it may also improve breast cancer outcomes. ...CONCLUSION: Metformin significantly lowers insulin levels, and it improves insulin resistance in nondiabetic women with breast cancer. …
If metformin lowers insulin levels in women with breast cancer, it may also improve breast cancer outcomes. ...CONCLUSI …
Metformin induces apoptosis of pancreatic cancer cells.
Wang LW, Li ZS, Zou DW, Jin ZD, Gao J, Xu GM. Wang LW, et al. World J Gastroenterol. 2008 Dec 21;14(47):7192-8. doi: 10.3748/wjg.14.7192. World J Gastroenterol. 2008. PMID: 19084933 Free PMC article.
AIM: To assess the role and mechanism of metformin in inducing apoptosis of pancreatic cancer cells. METHODS: The human pancreatic cancer cell lines ASPC-1, BxPc-3, PANC-1 and SW1990 were exposed to metformin. ...Enzymelinked immunosorbent assay (ELISA …
AIM: To assess the role and mechanism of metformin in inducing apoptosis of pancreatic cancer cells. METHODS: The human pancre …
Therapeutic metformin/AMPK activation promotes the angiogenic phenotype in the ERalpha negative MDA-MB-435 breast cancer model.
Phoenix KN, Vumbaca F, Claffey KP. Phoenix KN, et al. Breast Cancer Res Treat. 2009 Jan;113(1):101-11. doi: 10.1007/s10549-008-9916-5. Epub 2008 Feb 7. Breast Cancer Res Treat. 2009. PMID: 18256928 Free PMC article.
Systemic therapy with metformin was tested for efficacy in an orthotopic model of ERalpha negative breast cancer performed in athymic nude mice. ...The data presented here suggests that, although metformin significantly represses breast cancer cell gro …
Systemic therapy with metformin was tested for efficacy in an orthotopic model of ERalpha negative breast cancer performed in …
The antidiabetic drug metformin suppresses HER2 (erbB-2) oncoprotein overexpression via inhibition of the mTOR effector p70S6K1 in human breast carcinoma cells.
Vazquez-Martin A, Oliveras-Ferraros C, Menendez JA. Vazquez-Martin A, et al. Cell Cycle. 2009 Jan 1;8(1):88-96. doi: 10.4161/cc.8.1.7499. Epub 2009 Jan 1. Cell Cycle. 2009. PMID: 19106626 Free article.
We herein demonstrate that HER2 oncoprotein itself may represent a key cellular target involved in the anti-breast cancer actions of metformin. First, ectopical overexpression of HER2 oncogene significantly enhances metformin-induced breast cancer cell …
We herein demonstrate that HER2 oncoprotein itself may represent a key cellular target involved in the anti-breast cancer actions of …
An attempt at conservative treatment in selected cases of type I endometrial carcinoma (stage I a/G1) in young women.
Stanosz S. Stanosz S. Eur J Gynaecol Oncol. 2009;30(4):365-9. Eur J Gynaecol Oncol. 2009. PMID: 19761123
Moreover the women were given ergocryptine and metformin. RESULTS: After six months of therapy and during two years of follow-up histopathological examinations of material obtained from D&C the endometrial pattern was normal and free of cancer cells. ...
Moreover the women were given ergocryptine and metformin. RESULTS: After six months of therapy and during two years of follow-up hist …
Is it time to test metformin in breast cancer clinical trials?
Cazzaniga M, Bonanni B, Guerrieri-Gonzaga A, Decensi A. Cazzaniga M, et al. Cancer Epidemiol Biomarkers Prev. 2009 Mar;18(3):701-5. doi: 10.1158/1055-9965.EPI-08-0871. Epub 2009 Feb 24. Cancer Epidemiol Biomarkers Prev. 2009. PMID: 19240238
At the European Institute of Oncology, the Division of Cancer Prevention and Genetics is planning to conduct a clinical trial to evaluate the activity of metformin on tumor cell proliferation in breast cancer patients undergoing surgery. ...The confirmation o …
At the European Institute of Oncology, the Division of Cancer Prevention and Genetics is planning to conduct a clinical trial to eval …
Erlotinib-induced hepatitis complicated by fatal lactic acidosis in an elderly man with lung cancer.
Pellegrinotti M, Fimognari FL, Franco A, Repetto L, Pastorelli R. Pellegrinotti M, et al. Ann Pharmacother. 2009 Mar;43(3):542-5. doi: 10.1345/aph.1L468. Epub 2009 Mar 3. Ann Pharmacother. 2009. PMID: 19261961
DISCUSSION: In this patient, lactic acidosis was promoted by erlotinib-related hepatitis with initial liver failure (decreased lactate clearance), concomitant metformin treatment (increased lactate production), and acute renal deterioration (metformin accumulation). …
DISCUSSION: In this patient, lactic acidosis was promoted by erlotinib-related hepatitis with initial liver failure (decreased lactate clear …
Insulin sensitizers for women with polycystic ovarian syndrome.
Galal AF, Mitwally MF. Galal AF, et al. Expert Rev Endocrinol Metab. 2009 Mar;4(2):183-192. doi: 10.1586/17446651.4.2.183. Expert Rev Endocrinol Metab. 2009. PMID: 30780856
In addition, significant long-term health problems have been strongly linked to PCOS, with women suffering from the disorder having a significantly higher risk of diabetes, cardiovascular risk and some types of cancer, such as endometrial cancer. Although its etiolo …
In addition, significant long-term health problems have been strongly linked to PCOS, with women suffering from the disorder having a signif …
Metformin inhibits breast cancer cell growth, colony formation and induces cell cycle arrest in vitro.
Alimova IN, Liu B, Fan Z, Edgerton SM, Dillon T, Lind SE, Thor AD. Alimova IN, et al. Cell Cycle. 2009 Mar 15;8(6):909-15. doi: 10.4161/cc.8.6.7933. Epub 2009 Mar 26. Cell Cycle. 2009. PMID: 19221498
The anti-diabetic drug metformin reduces human cancer incidence and improves the survival of cancer patients, including those with breast cancer. We studied the activity of metformin against diverse molecular subtypes of breast cancer cel …
The anti-diabetic drug metformin reduces human cancer incidence and improves the survival of cancer patients, including …
Validation of anti-aging drugs by treating age-related diseases.
Blagosklonny MV. Blagosklonny MV. Aging (Albany NY). 2009 Mar 28;1(3):281-8. doi: 10.18632/aging.100034. Aging (Albany NY). 2009. PMID: 20157517 Free PMC article. Review.
Once a drug is used for treatment of any one chronic disease, its effect against other diseases (atherosclerosis, cancer, prostate enlargement, osteoporosis, insulin resistance, Alzheimer's and Parkinson's diseases, age-related macular degeneration) may be evaluated in the …
Once a drug is used for treatment of any one chronic disease, its effect against other diseases (atherosclerosis, cancer, prostate en …
Metformin, insulin, breast cancer and more..
Berstein LM. Berstein LM. Future Oncol. 2009 Apr;5(3):309-12. doi: 10.2217/fon.09.2. Future Oncol. 2009. PMID: 19374538
EVALUATION OF: Goodwin PJ, Pritchard KI, Ennis M, Clemons M, Graham M, Fantus IG: Insulin-lowering effects of metformin in women with early breast cancer. Clin. Breast Cancer 8(6), 501-505 (2008). This paper demonstrates that in breast cancer patients …
EVALUATION OF: Goodwin PJ, Pritchard KI, Ennis M, Clemons M, Graham M, Fantus IG: Insulin-lowering effects of metformin in women with …
AMP-activated protein kinase and cancer.
Wang W, Guan KL. Wang W, et al. Acta Physiol (Oxf). 2009 May;196(1):55-63. doi: 10.1111/j.1748-1716.2009.01980.x. Epub 2009 Feb 25. Acta Physiol (Oxf). 2009. PMID: 19243571 Review.
Elevated AMP/ATP ratio activates AMPK, which inhibits energy-consuming processes and activates energy-producing processes to restore the energy homeostasis inside the cell. AMPK activators, metformin and thiazolidinediones, are used for the treatment of type II diabetes. R …
Elevated AMP/ATP ratio activates AMPK, which inhibits energy-consuming processes and activates energy-producing processes to restore the ene …
Obesity related hyperinsulinaemia and hyperglycaemia and cancer development.
Becker S, Dossus L, Kaaks R. Becker S, et al. Arch Physiol Biochem. 2009 May;115(2):86-96. doi: 10.1080/13813450902878054. Arch Physiol Biochem. 2009. PMID: 19485704 Review.
Insulin resistance and hyperinsulinaemia are certainly key biological mechanisms underlying the relationship between adiposity and tumour development. The anti-diabetic drug, metformin, in addition to reduction of insulin resistance has also shown anti-tumour properties, a …
Insulin resistance and hyperinsulinaemia are certainly key biological mechanisms underlying the relationship between adiposity and tumour de …
Genome-wide inhibitory impact of the AMPK activator metformin on [kinesins, tubulins, histones, auroras and polo-like kinases] M-phase cell cycle genes in human breast cancer cells.
Oliveras-Ferraros C, Vazquez-Martin A, Menendez JA. Oliveras-Ferraros C, et al. Cell Cycle. 2009 May 15;8(10):1633-6. doi: 10.4161/cc.8.10.8406. Epub 2009 May 13. Cell Cycle. 2009. PMID: 19372741 Free article.
Prompted by the ever-growing scientific rationale for examining the antidiabetic drug metformin as a potential antitumor agent in breast cancer disease, we recently tested the hypothesis that the assessment of metformin-induced global changes in gene expressi …
Prompted by the ever-growing scientific rationale for examining the antidiabetic drug metformin as a potential antitumor agent in bre …
Chemical genomics identifies the unfolded protein response as a target for selective cancer cell killing during glucose deprivation.
Saito S, Furuno A, Sakurai J, Sakamoto A, Park HR, Shin-Ya K, Tsuruo T, Tomida A. Saito S, et al. Cancer Res. 2009 May 15;69(10):4225-34. doi: 10.1158/0008-5472.CAN-08-2689. Epub 2009 May 12. Cancer Res. 2009. PMID: 19435925
Here, we show that the UPR transcription program is disrupted by the antidiabetic biguanides metformin, buformin, and phenformin depending on cellular glucose availability. These drugs inhibit production of the UPR transcription activators XBP1 and ATF4 and induce massive …
Here, we show that the UPR transcription program is disrupted by the antidiabetic biguanides metformin, buformin, and phenformin depe …
Metformin induces unique biological and molecular responses in triple negative breast cancer cells.
Liu B, Fan Z, Edgerton SM, Deng XS, Alimova IN, Lind SE, Thor AD. Liu B, et al. Cell Cycle. 2009 Jul 1;8(13):2031-40. doi: 10.4161/cc.8.13.8814. Epub 2009 Jul 21. Cell Cycle. 2009. PMID: 19440038
Our data indicates that metformin has unique anti-TN breast cancer effects both in vitro and in vivo. It inhibits cell proliferation (with partial S phase arrest), colony formation and induces apoptosis via activation of the intrinsic and extrinsic signaling pathway …
Our data indicates that metformin has unique anti-TN breast cancer effects both in vitro and in vivo. It inhibits cell prolife …
mTOR inhibitors and the anti-diabetic biguanide metformin: new insights into the molecular management of breast cancer resistance to the HER2 tyrosine kinase inhibitor lapatinib (Tykerb).
Vázquez-Martín A, Oliveras-Ferraros C, del Barco S, Martín-Castillo B, Menéndez JA. Vázquez-Martín A, et al. Clin Transl Oncol. 2009 Jul;11(7):455-9. doi: 10.1007/s12094-009-0384-0. Clin Transl Oncol. 2009. PMID: 19574203 Review.
The unexpected ability of the anti-type II diabetes drug metformin to inactivate mTOR and decrease p70S6K1 activity further reveals that this biguanide, generally considered non-toxic and remarkably inexpensive, might be considered for new combinatorial lapatinib-based pro …
The unexpected ability of the anti-type II diabetes drug metformin to inactivate mTOR and decrease p70S6K1 activity further reveals t …
Enhancing CD8 T-cell memory by modulating fatty acid metabolism.
Pearce EL, Walsh MC, Cejas PJ, Harms GM, Shen H, Wang LS, Jones RG, Choi Y. Pearce EL, et al. Nature. 2009 Jul 2;460(7251):103-7. doi: 10.1038/nature08097. Epub 2009 Jun 3. Nature. 2009. PMID: 19494812 Free PMC article.
CD8 T cells, which have a crucial role in immunity to infection and cancer, are maintained in constant numbers, but on antigen stimulation undergo a developmental program characterized by distinct phases encompassing the expansion and then contraction of antigen-specific e …
CD8 T cells, which have a crucial role in immunity to infection and cancer, are maintained in constant numbers, but on antigen stimul …
Metformin in breast cancer: time for action.
Goodwin PJ, Ligibel JA, Stambolic V. Goodwin PJ, et al. J Clin Oncol. 2009 Jul 10;27(20):3271-3. doi: 10.1200/JCO.2009.22.1630. Epub 2009 Jun 1. J Clin Oncol. 2009. PMID: 19487373 No abstract available.
Metformin and pathologic complete responses to neoadjuvant chemotherapy in diabetic patients with breast cancer.
Jiralerspong S, Palla SL, Giordano SH, Meric-Bernstam F, Liedtke C, Barnett CM, Hsu L, Hung MC, Hortobagyi GN, Gonzalez-Angulo AM. Jiralerspong S, et al. J Clin Oncol. 2009 Jul 10;27(20):3297-302. doi: 10.1200/JCO.2009.19.6410. Epub 2009 Jun 1. J Clin Oncol. 2009. PMID: 19487376 Free PMC article.
PURPOSE: Population studies have suggested that metformin use in diabetic patients decreases cancer incidence and mortality. Metformin inhibits the growth of cancer cells in vitro and tumors in vivo. ...CONCLUSION: Diabetic patients with breast canc …
PURPOSE: Population studies have suggested that metformin use in diabetic patients decreases cancer incidence and mortality. …
Antidiabetic therapies affect risk of pancreatic cancer.
Li D, Yeung SC, Hassan MM, Konopleva M, Abbruzzese JL. Li D, et al. Gastroenterology. 2009 Aug;137(2):482-8. doi: 10.1053/j.gastro.2009.04.013. Epub 2009 Apr 16. Gastroenterology. 2009. PMID: 19375425 Free PMC article.
The risk of pancreatic cancer was estimated using unconditional logistic regression analysis. RESULTS: Diabetic patients who had taken metformin had a significantly lower risk of pancreatic cancer compared with those who had not taken metformin (odds r …
The risk of pancreatic cancer was estimated using unconditional logistic regression analysis. RESULTS: Diabetic patients who had take …
Metformin disrupts crosstalk between G protein-coupled receptor and insulin receptor signaling systems and inhibits pancreatic cancer growth.
Kisfalvi K, Eibl G, Sinnett-Smith J, Rozengurt E. Kisfalvi K, et al. Cancer Res. 2009 Aug 15;69(16):6539-45. doi: 10.1158/0008-5472.CAN-09-0418. Cancer Res. 2009. PMID: 19679549 Free PMC article.
Here, we determined whether metformin disrupts the crosstalk between insulin receptor and GPCR signaling in pancreatic cancer cells. ...These results raise the possibility that metformin could be a potential candidate in novel treatment strategies for human p …
Here, we determined whether metformin disrupts the crosstalk between insulin receptor and GPCR signaling in pancreatic cancer …
New users of metformin are at low risk of incident cancer: a cohort study among people with type 2 diabetes.
Libby G, Donnelly LA, Donnan PT, Alessi DR, Morris AD, Evans JM. Libby G, et al. Diabetes Care. 2009 Sep;32(9):1620-5. doi: 10.2337/dc08-2175. Epub 2009 Jun 29. Diabetes Care. 2009. PMID: 19564453 Free PMC article.

RESULTS: Cancer was diagnosed among 7.3% of 4,085 metformin users compared with 11.6% of 4,085 comparators, with median times to cancer of 3.5 and 2.6 years, respectively (P < 0.001). ...CONCLUSIONS: These results suggest that metformin use may be a

…
RESULTS: Cancer was diagnosed among 7.3% of 4,085 metformin users compared with 11.6% of 4,085 comparators, with median times …
The influence of glucose-lowering therapies on cancer risk in type 2 diabetes.
Currie CJ, Poole CD, Gale EA. Currie CJ, et al. Diabetologia. 2009 Sep;52(9):1766-77. doi: 10.1007/s00125-009-1440-6. Epub 2009 Jul 2. Diabetologia. 2009. PMID: 19572116
Compared with metformin, insulin therapy increased the risk of colorectal (HR 1.69, 95% CI 1.23-2.33) or pancreatic cancer (HR 4.63, 95% CI 2.64-8.10), but did not influence the risk of breast or prostate cancer. ...CONCLUSIONS/INTERPRETATION: Those on insuli …
Compared with metformin, insulin therapy increased the risk of colorectal (HR 1.69, 95% CI 1.23-2.33) or pancreatic cancer (HR …
Expanding roles for AMP-activated protein kinase in neuronal survival and autophagy.
Poels J, Spasić MR, Callaerts P, Norga KK. Poels J, et al. Bioessays. 2009 Sep;31(9):944-52. doi: 10.1002/bies.200900003. Bioessays. 2009. PMID: 19644919 Review.
In physiological situations, AMPK senses energy deficiency (in the form of an increased AMP/ATP ratio), but it is also activated by metabolic insults, such as glucose or oxygen deprivation. Metformin, one of the most widely prescribed anti-diabetic drugs, exerts its action …
In physiological situations, AMPK senses energy deficiency (in the form of an increased AMP/ATP ratio), but it is also activated by metaboli …
Is it the time for metformin to take place in adjuvant treatment of Her-2 positive breast cancer? Teaching new tricks to old dogs.
Yurekli BS, Karaca B, Cetinkalp S, Uslu R. Yurekli BS, et al. Med Hypotheses. 2009 Oct;73(4):606-7. doi: 10.1016/j.mehy.2009.05.027. Epub 2009 Jun 27. Med Hypotheses. 2009. PMID: 19560877
It seems that insulin may signal to activate a cascade of proliferative and anti-apoptotic events in the cancer cell. Metformin, an oral anti-diabetic known for 50 years, may also have direct effects on cancer cells. Metformin causes Her-2 suppression …
It seems that insulin may signal to activate a cascade of proliferative and anti-apoptotic events in the cancer cell. Metformin …
Role of insulin, insulin-like growth factor-1, hyperglycaemic food and milk consumption in the pathogenesis of acne vulgaris.
Melnik BC, Schmitz G. Melnik BC, et al. Exp Dermatol. 2009 Oct;18(10):833-41. doi: 10.1111/j.1600-0625.2009.00924.x. Epub 2009 Aug 25. Exp Dermatol. 2009. PMID: 19709092 Review.
Acne is proposed to be an IGF-1-mediated disease, modified by diets and smoking increasing insulin/IGF1-signalling. Metformin treatment, and diets low in milk protein content and glycaemic index reduce increased IGF-1 signalling. Persistent acne in adulthood with high IGF- …
Acne is proposed to be an IGF-1-mediated disease, modified by diets and smoking increasing insulin/IGF1-signalling. Metformin treatme …
Metformin selectively targets cancer stem cells, and acts together with chemotherapy to block tumor growth and prolong remission.
Hirsch HA, Iliopoulos D, Tsichlis PN, Struhl K. Hirsch HA, et al. Cancer Res. 2009 Oct 1;69(19):7507-11. doi: 10.1158/0008-5472.CAN-09-2994. Epub 2009 Sep 14. Cancer Res. 2009. PMID: 19752085 Free PMC article.
Here, we show that low doses of metformin, a standard drug for diabetes, inhibits cellular transformation and selectively kills cancer stem cells in four genetically different types of breast cancer. The combination of metformin and a well-defined chem …
Here, we show that low doses of metformin, a standard drug for diabetes, inhibits cellular transformation and selectively kills ca …
Metformin use and prostate cancer in Caucasian men: results from a population-based case-control study.
Wright JL, Stanford JL. Wright JL, et al. Cancer Causes Control. 2009 Nov;20(9):1617-22. doi: 10.1007/s10552-009-9407-y. Epub 2009 Aug 4. Cancer Causes Control. 2009. PMID: 19653109 Free PMC article.
PURPOSE: Metformin is a commonly used medication for type II diabetes mellitus. Epidemiologic studies have suggested a decreased relative risk of cancer with metformin use, and preclinical studies of prostate cancer (PCa) have shown antitumor activity …
PURPOSE: Metformin is a commonly used medication for type II diabetes mellitus. Epidemiologic studies have suggested a decreased rela …
If mammalian target of metformin indirectly is mammalian target of rapamycin, then the insulin-like growth factor-1 receptor axis will audit the efficacy of metformin in cancer clinical trials.
Vazquez-Martin A, Oliveras-Ferraros C, Del Barco S, Martin-Castillo B, Menendez JA. Vazquez-Martin A, et al. J Clin Oncol. 2009 Nov 20;27(33):e207-9; author reply e210. doi: 10.1200/JCO.2009.24.5456. Epub 2009 Oct 26. J Clin Oncol. 2009. PMID: 19858375 No abstract available.
Sulphonylureas and cancer: a case-control study.
Monami M, Lamanna C, Balzi D, Marchionni N, Mannucci E. Monami M, et al. Acta Diabetol. 2009 Dec;46(4):279-84. doi: 10.1007/s00592-008-0083-2. Epub 2008 Dec 10. Acta Diabetol. 2009. PMID: 19082520
After adjusting for concomitant therapies, exposure to metformin and gliclazide for more than 36 months was associated with a significant reduction in the risk of cancer (adj. ...Treatment with insulin, thiazolidinediones, or acarbose, was not associated with signif …
After adjusting for concomitant therapies, exposure to metformin and gliclazide for more than 36 months was associated with a signifi …
Diabetes and cancer.
Vigneri P, Frasca F, Sciacca L, Pandini G, Vigneri R. Vigneri P, et al. Endocr Relat Cancer. 2009 Dec;16(4):1103-23. doi: 10.1677/ERC-09-0087. Epub 2009 Jul 20. Endocr Relat Cancer. 2009. PMID: 19620249 Review.
Obesity, hyperglycemia, and increased oxidative stress may also contribute to increased cancer risk in diabetes. While anti-diabetic drugs have a minor influence on cancer risk (except perhaps the biguanide metformin that apparently reduces the risk), drugs u …
Obesity, hyperglycemia, and increased oxidative stress may also contribute to increased cancer risk in diabetes. While anti-diabetic …
Metformin is a potent inhibitor of endometrial cancer cell proliferation--implications for a novel treatment strategy.
Cantrell LA, Zhou C, Mendivil A, Malloy KM, Gehrig PA, Bae-Jump VL. Cantrell LA, et al. Gynecol Oncol. 2010 Jan;116(1):92-8. doi: 10.1016/j.ygyno.2009.09.024. Epub 2009 Oct 12. Gynecol Oncol. 2010. PMID: 19822355 Free PMC article.
Recent epidemiological evidence suggests that metformin may lower cancer risk and reduce rates of cancer deaths among diabetic patients. In order to better understand metformin's anti-tumorigenic potential, our goal was to assess the effect of metfo …
Recent epidemiological evidence suggests that metformin may lower cancer risk and reduce rates of cancer deaths among d …
Incorporating the antidiabetic drug metformin in HER2-positive breast cancer treated with neo-adjuvant chemotherapy and trastuzumab: an ongoing clinical-translational research experience at the Catalan Institute of Oncology.
Martin-Castillo B, Dorca J, Vazquez-Martin A, Oliveras-Ferraros C, Lopez-Bonet E, Garcia M, Del Barco S, Menendez JA. Martin-Castillo B, et al. Ann Oncol. 2010 Jan;21(1):187-9. doi: 10.1093/annonc/mdp494. Epub 2009 Nov 2. Ann Oncol. 2010. PMID: 19884247 Free article. No abstract available.
Metformin extends life span of HER-2/neu transgenic mice and in combination with melatonin inhibits growth of transplantable tumors in vivo.
Anisimov VN, Egormin PA, Piskunova TS, Popovich IG, Tyndyk ML, Yurova MN, Zabezhinski MA, Anikin IV, Karkach AS, Romanyukha AA. Anisimov VN, et al. Cell Cycle. 2010 Jan 1;9(1):188-97. doi: 10.4161/cc.9.1.10407. Epub 2010 Jan 22. Cell Cycle. 2010. PMID: 20016287
Population studies have shown that treatment with the antidiabetic biguanide metformin significantly reduced cancer risk. In our animal studies, metformin delayed the onset of mammary adenocarcinoma (MAC) in transgenic HER-2/neu mice but not the onset of spon …
Population studies have shown that treatment with the antidiabetic biguanide metformin significantly reduced cancer risk. In o …
Excretion of estrogens, catecholestrogens and phytoestrogens in carriers of BRCA1 gene mutations: effects of metformin.
Berstein LM, Koskela A, Boyarkina MP, Adlercreutz H. Berstein LM, et al. Neoplasma. 2010;57(4):333-8. doi: 10.4149/neo_2010_04_333. Neoplasma. 2010. PMID: 20429624
The treatment after the baseline laboratory investigation of 6 women from postmenopausal group with the antidiabetic biguanide metformin for 3 months was associated with decreases in the excretion rates of 4-hydroxyestradiol, 2-methoxyestradiol, and 16-epiestriol and did n …
The treatment after the baseline laboratory investigation of 6 women from postmenopausal group with the antidiabetic biguanide metformin …
[Effect of previous diabetes therapy on tumor receptor phenotype in breast cancer: comparison of metformin and sulphonylurea derivatives].
Bershteĭn LM, Boriakina MP, Turkevich EA, Tsyrlina EV, Semiglazov VF. Bershteĭn LM, et al. Vopr Onkol. 2010;56(3):312-6. Vopr Onkol. 2010. PMID: 20804053 Russian.
According to some existing data, unlike sulphonylurea (SU) and insulin derivatives, treatment with biguanide metformin, for reasons still unknown, may diminish breast cancer (BC) morbidity in diabetic females. ...SU drugs were received for at least 12 months by 22 p …
According to some existing data, unlike sulphonylurea (SU) and insulin derivatives, treatment with biguanide metformin, for reasons s …
Epidemiology of pancreatic cancer: an update.
Maisonneuve P, Lowenfels AB. Maisonneuve P, et al. Dig Dis. 2010;28(4-5):645-56. doi: 10.1159/000320068. Epub 2010 Nov 18. Dig Dis. 2010. PMID: 21088417 Review.
Pancreatic cancer, although infrequent, has a very poor prognosis, making it one of the 4 or 5 most common causes of cancer mortality in developed countries. ...A family history of pancreatic cancer is associated with an increased risk of pancreatic cancer …
Pancreatic cancer, although infrequent, has a very poor prognosis, making it one of the 4 or 5 most common causes of cancer mo …
[Influence of metformin and N-acetylcysteine on hormonal and genotoxic effects of estrogens and glucose in convalescent cancer patients].
Bershteĭn LM, Vasil'ev DA, Poroshina TE, Kovalenko IG, Boiarkina MP, Revskoĭ SIu, Kovalevskiĭ AIu. Bershteĭn LM, et al. Vopr Onkol. 2010;56(6):664-70. Vopr Onkol. 2010. PMID: 21395121 Clinical Trial. Russian.
Our study involved 25 postmenopausal patients (endometrial carcinoma--16, breast (6) and colorectal (3) cancer, aged 56.8 +/- 0.9). All patients were in clinical remission. None had received any specific therapy for at least 12 months. After a laboratory endocrine-genotoxi …
Our study involved 25 postmenopausal patients (endometrial carcinoma--16, breast (6) and colorectal (3) cancer, aged 56.8 +/- 0.9). A …
Role of Pioglitazone with Metformin or Glimepiride on Oxidative Stress-induced Nuclear Damage and Reproductive Toxicity in Diabetic Rats.
Rabbani SI, Devi K, Khanam S. Rabbani SI, et al. Malays J Med Sci. 2010 Jan;17(1):3-11. Malays J Med Sci. 2010. PMID: 22135519 Free PMC article.
BACKGROUND: Oxidative stress due to improper control of blood glucose in chronic diabetes plays a major role in the development of secondary complications including cancer and birth defect. The aim of this study is to evaluate the protective effect of combination of piogli …
BACKGROUND: Oxidative stress due to improper control of blood glucose in chronic diabetes plays a major role in the development of secondary …
Diabetes, insulin treatment, and cancer risk: what is the evidence?
Azar M, Lyons TJ. Azar M, et al. F1000 Med Rep. 2010 Jan 18;2:4. doi: 10.3410/M2-4. F1000 Med Rep. 2010. PMID: 20948845 Free PMC article.
Diabetes, in particular type 2, is associated with an increased incidence of cancer. Although the mortality attributable to cancer in type 2 diabetes is overshadowed by that due to cardiovascular disease, emerging data from epidemiologic studies suggest that insulin …
Diabetes, in particular type 2, is associated with an increased incidence of cancer. Although the mortality attributable to cancer …
Metformin decreases IGF1-induced cell proliferation and protein synthesis through AMP-activated protein kinase in cultured bovine granulosa cells.
Tosca L, Ramé C, Chabrolle C, Tesseraud S, Dupont J. Tosca L, et al. Reproduction. 2010 Feb;139(2):409-18. doi: 10.1530/REP-09-0351. Epub 2009 Nov 11. Reproduction. 2010. PMID: 19906888
It may also reduce the risk of cancer. We have recently shown that metformin treatment decreases steroidogenesis through AMP-activated kinase (AMPK) in granulosa cells of various species. ...Adenovirus-mediated expression of dominant-negative AMPK totally abolished …
It may also reduce the risk of cancer. We have recently shown that metformin treatment decreases steroidogenesis through AMP-a …
Metformin associated with lower cancer mortality in type 2 diabetes: ZODIAC-16.
Landman GW, Kleefstra N, van Hateren KJ, Groenier KH, Gans RO, Bilo HJ. Landman GW, et al. Diabetes Care. 2010 Feb;33(2):322-6. doi: 10.2337/dc09-1380. Epub 2009 Nov 16. Diabetes Care. 2010. PMID: 19918015 Free PMC article.
OBJECTIVE: Several studies have suggested an association between specific diabetes treatment and cancer mortality. We studied the association between metformin use and cancer mortality in a prospectively followed cohort. ...CONCLUSIONS: In general, patients w …
OBJECTIVE: Several studies have suggested an association between specific diabetes treatment and cancer mortality. We studied the ass …
AMPK as a metabolic tumor suppressor: control of metabolism and cell growth.
Luo Z, Zang M, Guo W. Luo Z, et al. Future Oncol. 2010 Mar;6(3):457-70. doi: 10.2217/fon.09.174. Future Oncol. 2010. PMID: 20222801 Free PMC article. Review.
Recent studies indicate that AMPK plays a role in linking metabolic syndrome and cancer. AMPK is an essential mediator of the tumor suppressor LKB1 and could be suppressed in cancer cells containing loss-of-function mutations of LKB1 or containing active mutations o …
Recent studies indicate that AMPK plays a role in linking metabolic syndrome and cancer. AMPK is an essential mediator of the tumor s …
Thailand Diabetic Registry cohort: predicting death in Thai diabetic patients and causes of death.
Pratipanawatr T, Rawdaree P, Chetthakul T, Bunnag P, Ngarmukos C, Benjasuratwong Y, Leelawatana R, Kosachunhanun N, Plengvidhya N, Deerochanawong C, Suwanwalaikorn S, Krittiyawong S, Mongkolsomlit S, Komoltri C. Pratipanawatr T, et al. J Med Assoc Thai. 2010 Mar;93 Suppl 3:S12-20. J Med Assoc Thai. 2010. PMID: 21299087
There was an increased risk of death associated with age, type of healthcare plan, lower education, insulin use, smoking, history of coronary artery disease and cerebrovascular disease, serum creatinine and high HbA1c. Lipid-lowering medication and metformin decreased the …
There was an increased risk of death associated with age, type of healthcare plan, lower education, insulin use, smoking, history of coronar …
Targeting cancer cell metabolism: the combination of metformin and 2-deoxyglucose induces p53-dependent apoptosis in prostate cancer cells.
Ben Sahra I, Laurent K, Giuliano S, Larbret F, Ponzio G, Gounon P, Le Marchand-Brustel Y, Giorgetti-Peraldi S, Cormont M, Bertolotto C, Deckert M, Auberger P, Tanti JF, Bost F. Ben Sahra I, et al. Cancer Res. 2010 Mar 15;70(6):2465-75. doi: 10.1158/0008-5472.CAN-09-2782. Epub 2010 Mar 9. Cancer Res. 2010. PMID: 20215500
Targeting cancer cell metabolism is a new promising strategy to fight cancer. Metformin, a widely used antidiabetic agent, exerts antitumoral and antiproliferative action. ...The combination of the two drugs was much more harmful for cancer cells than …
Targeting cancer cell metabolism is a new promising strategy to fight cancer. Metformin, a widely used antidiabetic age …
Metformin: a therapeutic opportunity in breast cancer.
Gonzalez-Angulo AM, Meric-Bernstam F. Gonzalez-Angulo AM, et al. Clin Cancer Res. 2010 Mar 15;16(6):1695-700. doi: 10.1158/1078-0432.CCR-09-1805. Epub 2010 Mar 9. Clin Cancer Res. 2010. PMID: 20215559 Free PMC article. Review.
At the level of cell signaling, metformin activates AMPK. There are extensive preclinical data showing the anticancer effects of metformin in all breast cancer subtypes as well as in cytotoxic therapy-resistant models. These data, and the epidemiological and …
At the level of cell signaling, metformin activates AMPK. There are extensive preclinical data showing the anticancer effects of m …
Metformin and cancer: doses, mechanisms and the dandelion and hormetic phenomena.
Martin-Castillo B, Vazquez-Martin A, Oliveras-Ferraros C, Menendez JA. Martin-Castillo B, et al. Cell Cycle. 2010 Mar 15;9(6):1057-64. doi: 10.4161/cc.9.6.10994. Epub 2010 Mar 15. Cell Cycle. 2010. PMID: 20305377 Review.
Epidemiological studies have confirmed that metformin, but not other anti-diabetic drugs, significantly reduces cancer incidence and improves cancer patients' survival in type 2 diabetics. ...Ongoing chemopreventive, neoadjuvant and adjuvant trials should def …
Epidemiological studies have confirmed that metformin, but not other anti-diabetic drugs, significantly reduces cancer inciden …
Insulin analogues and cancer risk: cause for concern or cause celebre?
Pollak M, Russell-Jones D. Pollak M, et al. Int J Clin Pract. 2010 Apr;64(5):628-36. doi: 10.1111/j.1742-1241.2010.02354.x. Epub 2010 Feb 26. Int J Clin Pract. 2010. PMID: 20201993 Review.
People with diabetes, particularly those with type 2 diabetes, may be at an increased risk of cancer. Furthermore, their cancer risk may be modified by treatment choices. In this respect, metformin may be protective, whereas insulin and insulin analogues can …
People with diabetes, particularly those with type 2 diabetes, may be at an increased risk of cancer. Furthermore, their cancer …
Role of human placental apical membrane transporters in the efflux of glyburide, rosiglitazone, and metformin.
Hemauer SJ, Patrikeeva SL, Nanovskaya TN, Hankins GD, Ahmed MS. Hemauer SJ, et al. Am J Obstet Gynecol. 2010 Apr;202(4):383.e1-7. doi: 10.1016/j.ajog.2010.01.035. Am J Obstet Gynecol. 2010. PMID: 20350646 Free PMC article.
STUDY DESIGN: Inside-out brush border membrane vesicles from term placentas were used to determine the efflux of glyburide, rosiglitazone, and metformin by P-glycoprotein, breast cancer resistance protein, and multidrug resistance protein. ...Metformin was tr …
STUDY DESIGN: Inside-out brush border membrane vesicles from term placentas were used to determine the efflux of glyburide, rosiglitazone, a …
Insulin, insulin resistance, obesity, and cancer.
Gallagher EJ, LeRoith D. Gallagher EJ, et al. Curr Diab Rep. 2010 Apr;10(2):93-100. doi: 10.1007/s11892-010-0101-y. Curr Diab Rep. 2010. PMID: 20425567 Review.
Patients with type 2 diabetes are reported to have a worse response to cancer chemotherapy, have more complications, and have a poorer prognosis than patients with cancer without diabetes. Studies also have reported that insulin, insulin secretagogues, and metfor …
Patients with type 2 diabetes are reported to have a worse response to cancer chemotherapy, have more complications, and have a poore …
Diabetes therapy and cancer risk: causal effects and other plausible explanations.
Hernández-Díaz S, Adami HO. Hernández-Díaz S, et al. Diabetologia. 2010 May;53(5):802-8. doi: 10.1007/s00125-010-1675-2. Epub 2010 Feb 23. Diabetologia. 2010. PMID: 20177658
Four reports in Diabetologia presented data on the association between hypoglycaemic agents and the risk of cancer. One study showed a higher risk of cancer overall in subjects with diabetes receiving insulin or sulfonylureas than in those on metformin. ...Ho …
Four reports in Diabetologia presented data on the association between hypoglycaemic agents and the risk of cancer. One study showed …
Metformin supplementation and life span in Fischer-344 rats.
Smith DL Jr, Elam CF Jr, Mattison JA, Lane MA, Roth GS, Ingram DK, Allison DB. Smith DL Jr, et al. J Gerontol A Biol Sci Med Sci. 2010 May;65(5):468-74. doi: 10.1093/gerona/glq033. Epub 2010 Mar 19. J Gerontol A Biol Sci Med Sci. 2010. PMID: 20304770 Free PMC article.
Calorie restriction (CR) has been known for more than 70 years to extend life span and delay disease in rodent models. Metformin administration in rodent disease models has been shown to delay cancer incidence and progression, reduce cardiovascular disease and exten …
Calorie restriction (CR) has been known for more than 70 years to extend life span and delay disease in rodent models. Metformin admi …
Crosstalk between insulin/insulin-like growth factor-1 receptors and G protein-coupled receptor signaling systems: a novel target for the antidiabetic drug metformin in pancreatic cancer.
Rozengurt E, Sinnett-Smith J, Kisfalvi K. Rozengurt E, et al. Clin Cancer Res. 2010 May 1;16(9):2505-11. doi: 10.1158/1078-0432.CCR-09-2229. Epub 2010 Apr 13. Clin Cancer Res. 2010. PMID: 20388847 Free PMC article.
Recent results show that metformin-induced activation of AMPK disrupts crosstalk between insulin/IGF-1 receptor and GPCR signaling in pancreatic cancer cells and inhibits the growth of these cells in xenograft models. Given that insulin/IGF-1 and GPCRs are implicate …
Recent results show that metformin-induced activation of AMPK disrupts crosstalk between insulin/IGF-1 receptor and GPCR signaling in …
[Diabetes, insulin, insulin analogues, and cancer].
Müssig K, Staiger H, Kantartzis K, Fritsche A, Kanz L, Häring HU. Müssig K, et al. Dtsch Med Wochenschr. 2010 May;135(18):924-9. doi: 10.1055/s-0030-1253681. Epub 2010 Apr 27. Dtsch Med Wochenschr. 2010. PMID: 20425680 Review. German.
A diabetes therapy with insulin or sulfonylureas, which leads to elevated exogenous or endogenous insulin levels, appears to be related with an increased cancer risk, whereas administration of metformin or thiazolidinediones, which is associated with a decrease of i …
A diabetes therapy with insulin or sulfonylureas, which leads to elevated exogenous or endogenous insulin levels, appears to be related with …
Metformin in cancer therapy: a new perspective for an old antidiabetic drug?
Ben Sahra I, Le Marchand-Brustel Y, Tanti JF, Bost F. Ben Sahra I, et al. Mol Cancer Ther. 2010 May;9(5):1092-9. doi: 10.1158/1535-7163.MCT-09-1186. Epub 2010 May 4. Mol Cancer Ther. 2010. PMID: 20442309 Review.
First, epidemiological studies show a decrease in cancer incidence in metformin-treated patients. Second, metformin decreases insulin resistance and indirectly reduces insulin level, a beneficial effect because insulin promotes cancer cell growth. Thir …
First, epidemiological studies show a decrease in cancer incidence in metformin-treated patients. Second, metformin dec …
Obesity, hyperinsulinemia and breast cancer: novel targets and a novel role for metformin.
Wysocki PJ, Wierusz-Wysocka B. Wysocki PJ, et al. Expert Rev Mol Diagn. 2010 May;10(4):509-19. doi: 10.1586/erm.10.22. Expert Rev Mol Diagn. 2010. PMID: 20465505 Review.
Metformin has been shown to inhibit proliferation, invasion and angiogenesis of neoplastic cells and to overcome resistance of breast cancer to chemotherapy, hormonal therapy and HER2 inhibition. ...Several currently ongoing Phase II and III clinical studies are eva …
Metformin has been shown to inhibit proliferation, invasion and angiogenesis of neoplastic cells and to overcome resistance of breast …
Metformin, independent of AMPK, inhibits mTORC1 in a rag GTPase-dependent manner.
Kalender A, Selvaraj A, Kim SY, Gulati P, Brûlé S, Viollet B, Kemp BE, Bardeesy N, Dennis P, Schlager JJ, Marette A, Kozma SC, Thomas G. Kalender A, et al. Cell Metab. 2010 May 5;11(5):390-401. doi: 10.1016/j.cmet.2010.03.014. Cell Metab. 2010. PMID: 20444419 Free PMC article.
It is thought that agents that increase the cellular AMP/ATP ratio, such as the antidiabetic biguanides metformin and phenformin, inhibit mTORC1 through AMPK activation of TSC1/2-dependent or -independent mechanisms. ...Consistent with these observations, in two distinct p …
It is thought that agents that increase the cellular AMP/ATP ratio, such as the antidiabetic biguanides metformin and phenformin, inh …
Metformin blocks the stimulative effect of a high-energy diet on colon carcinoma growth in vivo and is associated with reduced expression of fatty acid synthase.
Algire C, Amrein L, Zakikhani M, Panasci L, Pollak M. Algire C, et al. Endocr Relat Cancer. 2010 Jun 1;17(2):351-60. doi: 10.1677/ERC-09-0252. Print 2010 Jun. Endocr Relat Cancer. 2010. PMID: 20228137
The molecular mechanisms responsible for the association of obesity with adverse colon cancer outcomes are poorly understood. We investigated the effects of a high-energy diet on growth of an in vivo colon cancer model. ...We observed that metformin blocked t …
The molecular mechanisms responsible for the association of obesity with adverse colon cancer outcomes are poorly understood. We inve …
Long-term metformin use is associated with decreased risk of breast cancer.
Bodmer M, Meier C, Krähenbühl S, Jick SS, Meier CR. Bodmer M, et al. Diabetes Care. 2010 Jun;33(6):1304-8. doi: 10.2337/dc09-1791. Epub 2010 Mar 18. Diabetes Care. 2010. PMID: 20299480 Free PMC article.
Neither short-term metformin use nor use of sulfonylureas or other antidiabetes drugs was associated with a materially altered risk for breast cancer. CONCLUSIONS: A decreased risk of breast cancer was observed in female patients with type 2 diabetes using …
Neither short-term metformin use nor use of sulfonylureas or other antidiabetes drugs was associated with a materially altered risk f …
Glycated hemoglobin and antidiabetic strategies as risk factors for hepatocellular carcinoma.
Donadon V, Balbi M, Valent F, Avogaro A. Donadon V, et al. World J Gastroenterol. 2010 Jun 28;16(24):3025-32. doi: 10.3748/wjg.v16.i24.3025. World J Gastroenterol. 2010. PMID: 20572306 Free PMC article.
Antidiabetic treatment with metformin was more common among cirrhotic and control DM2 subjects than among cases with HCC. In both series of multivariate analyses, treatment with metformin significantly reduced the risk of HCC by more than 80% compared with sulphonyl …
Antidiabetic treatment with metformin was more common among cirrhotic and control DM2 subjects than among cases with HCC. In both ser …
The combination of metformin and 2-deoxyglucose inhibits autophagy and induces AMPK-dependent apoptosis in prostate cancer cells.
Ben Sahra I, Tanti JF, Bost F. Ben Sahra I, et al. Autophagy. 2010 Jul;6(5):670-1. doi: 10.4161/auto.6.5.12434. Autophagy. 2010. PMID: 20559023
Targeting cancer cell metabolism is a new promising strategy to fight cancer. Metformin, a widely used antidiabetic agent, and 2-deoxyglucose (2DG) drastically affect cancer cell metabolism. Recently, we showed that the combination of the two drugs was …
Targeting cancer cell metabolism is a new promising strategy to fight cancer. Metformin, a widely used antidiabetic age …
Metformin suppresses azoxymethane-induced colorectal aberrant crypt foci by activating AMP-activated protein kinase.
Hosono K, Endo H, Takahashi H, Sugiyama M, Uchiyama T, Suzuki K, Nozaki Y, Yoneda K, Fujita K, Yoneda M, Inamori M, Tomatsu A, Chihara T, Shimpo K, Nakagama H, Nakajima A. Hosono K, et al. Mol Carcinog. 2010 Jul;49(7):662-71. doi: 10.1002/mc.20637. Mol Carcinog. 2010. PMID: 20564343
Furthermore, to examine the indirect effect of metformin, the insulin resistance status and the serum lipid levels were assessed. Treatment with metformin significantly reduced ACF formation. ...As metformin is already used daily as an antidiabetic drug, it m …
Furthermore, to examine the indirect effect of metformin, the insulin resistance status and the serum lipid levels were assessed. Tre …
Metformin blocks migration and invasion of tumour cells by inhibition of matrix metalloproteinase-9 activation through a calcium and protein kinase Calpha-dependent pathway: phorbol-12-myristate-13-acetate-induced/extracellular signal-regulated kinase/activator protein-1.
Hwang YP, Jeong HG. Hwang YP, et al. Br J Pharmacol. 2010 Jul;160(5):1195-211. doi: 10.1111/j.1476-5381.2010.00762.x. Br J Pharmacol. 2010. PMID: 20590612 Free PMC article.
BACKGROUND AND PURPOSE: Population studies have revealed that treatment with the anti-diabetic drug metformin is significantly associated with reduced cancer risk, but the underlying mode of action has not been elucidated. ...Metformin therefore has the poten …
BACKGROUND AND PURPOSE: Population studies have revealed that treatment with the anti-diabetic drug metformin is significantly associ …
Protective effect of metformin in CD1 mice placed on a high carbohydrate-high fat diet.
Hou M, Venier N, Sugar L, Musquera M, Pollak M, Kiss A, Fleshner N, Klotz L, Venkateswaran V. Hou M, et al. Biochem Biophys Res Commun. 2010 Jul 2;397(3):537-42. doi: 10.1016/j.bbrc.2010.05.152. Epub 2010 Jun 2. Biochem Biophys Res Commun. 2010. PMID: 20573602
We hypothesize that metformin may have a protective effect against prostate cancer progression by affecting metabolisms associated with high energy intake. ...There was no observed metformin-related hepato-toxicity in any of the groups. In summary, metform …
We hypothesize that metformin may have a protective effect against prostate cancer progression by affecting metabolisms associ …
Metformin and rapamycin have distinct effects on the AKT pathway and proliferation in breast cancer cells.
Zakikhani M, Blouin MJ, Piura E, Pollak MN. Zakikhani M, et al. Breast Cancer Res Treat. 2010 Aug;123(1):271-9. doi: 10.1007/s10549-010-0763-9. Epub 2010 Feb 5. Breast Cancer Res Treat. 2010. PMID: 20135346
Rapamycin and its analogues inhibit mTOR, which leads to decreased protein synthesis and decreased cancer cell proliferation in many experimental systems. Adenosine 5'- monophosphate-activated protein kinase (AMPK) activators such as metformin have similar actions, …
Rapamycin and its analogues inhibit mTOR, which leads to decreased protein synthesis and decreased cancer cell proliferation in many …
Glucose-lowering agents and cancer mortality rates in type 2 diabetes: assessing effects of time-varying exposure.
Bowker SL, Yasui Y, Veugelers P, Johnson JA. Bowker SL, et al. Diabetologia. 2010 Aug;53(8):1631-7. doi: 10.1007/s00125-010-1750-8. Epub 2010 Apr 21. Diabetologia. 2010. PMID: 20407744
AIMS/HYPOTHESIS: We explored the relationship between glucose-lowering agents and cancer mortality rates in type 2 diabetes patients, hypothesising a decreased risk of cancer mortality with metformin use and a dose-risk gradient for insulin therapy. ...RESULT …
AIMS/HYPOTHESIS: We explored the relationship between glucose-lowering agents and cancer mortality rates in type 2 diabetes patients, …
Metformin and cancer: licence to heal?
Papanas N, Maltezos E, Mikhailidis DP. Papanas N, et al. Expert Opin Investig Drugs. 2010 Aug;19(8):913-7. doi: 10.1517/13543784.2010.499122. Expert Opin Investig Drugs. 2010. PMID: 20557275
Importantly, metformin is nowadays emerging as an agent that has the potential to protect from cancer. ...These observations are supported by in vitro and in vivo evidence that metformin inhibits the growth of cancer cells. The mechanisms underlying th …
Importantly, metformin is nowadays emerging as an agent that has the potential to protect from cancer. ...These observations a …
Modern approach to metabolic rehabilitation of cancer patients: biguanides (phenformin and metformin) and beyond.
Berstein LM. Berstein LM. Future Oncol. 2010 Aug;6(8):1313-23. doi: 10.2217/fon.10.87. Future Oncol. 2010. PMID: 20799876 Review.
Comparing the experience accumulated for more than 40 years in the Laboratory of Endocrinology of Petrov Institute of Oncology (St Petersburg, Russia) with similar approaches practiced elsewhere, evidence supports the reasonability of metabolic rehabilitation of patients sufferin …
Comparing the experience accumulated for more than 40 years in the Laboratory of Endocrinology of Petrov Institute of Oncology (St Petersbur …
Cancer risk in diabetic patients treated with insulin glargine?
[No authors listed] [No authors listed] Prescrire Int. 2010 Aug;19(108):162-3. Prescrire Int. 2010. PMID: 20939447
Four European epidemiological studies published in 2009 examined the risk of cancer in diabetic patients treated with insulin glargine. One of these studies, conducted in Germany, showed a statistically significant dose-dependent increase in the risk of cancer. Two …
Four European epidemiological studies published in 2009 examined the risk of cancer in diabetic patients treated with insulin glargin …
Oxidative stress in cancer associated fibroblasts drives tumor-stroma co-evolution: A new paradigm for understanding tumor metabolism, the field effect and genomic instability in cancer cells.
Martinez-Outschoorn UE, Balliet RM, Rivadeneira DB, Chiavarina B, Pavlides S, Wang C, Whitaker-Menezes D, Daumer KM, Lin Z, Witkiewicz AK, Flomenberg N, Howell A, Pestell RG, Knudsen ES, Sotgia F, Lisanti MP. Martinez-Outschoorn UE, et al. Cell Cycle. 2010 Aug 15;9(16):3256-76. doi: 10.4161/cc.9.16.12553. Epub 2010 Aug 28. Cell Cycle. 2010. PMID: 20814239 Free PMC article.
Here, we propose a new paradigm to explain the powerful prognostic value of stromal Cav-1. In this model, cancer cells induce oxidative stress in cancer-associated fibroblasts, which then acts as a "metabolic" and "mutagenic" motor to drive tumor-stroma co-evolution …
Here, we propose a new paradigm to explain the powerful prognostic value of stromal Cav-1. In this model, cancer cells induce oxidati …
Dietary energy availability affects primary and metastatic breast cancer and metformin efficacy.
Phoenix KN, Vumbaca F, Fox MM, Evans R, Claffey KP. Phoenix KN, et al. Breast Cancer Res Treat. 2010 Sep;123(2):333-44. doi: 10.1007/s10549-009-0647-z. Epub 2009 Nov 22. Breast Cancer Res Treat. 2010. PMID: 20204498 Free PMC article.
Dietary energy restriction has been shown to repress both mammary tumorigenesis and aggressive mammary tumor growth in animal studies. Metformin, a caloric restriction mimetic, has a long history of safe use as an insulin sensitizer in diabetics and has been shown to reduc …
Dietary energy restriction has been shown to repress both mammary tumorigenesis and aggressive mammary tumor growth in animal studies. Me …
Metformin inhibits aromatase expression in human breast adipose stromal cells via stimulation of AMP-activated protein kinase.
Brown KA, Hunger NI, Docanto M, Simpson ER. Brown KA, et al. Breast Cancer Res Treat. 2010 Sep;123(2):591-6. doi: 10.1007/s10549-010-0834-y. Epub 2010 Mar 19. Breast Cancer Res Treat. 2010. PMID: 20300828
Consistent with the hypothesized actions of metformin to increase AMPK activity, treatment with 50 muM metformin results in a significant increase in phosphorylation of AMPK at Thr172. Interestingly, metformin also causes a significant increase in LKB1 protei …
Consistent with the hypothesized actions of metformin to increase AMPK activity, treatment with 50 muM metformin results in a …
Experience of malignancies with oral glucose-lowering drugs in the randomised controlled ADOPT (A Diabetes Outcome Progression Trial) and RECORD (Rosiglitazone Evaluated for Cardiovascular Outcomes and Regulation of Glycaemia in Diabetes) clinical trials.
Home PD, Kahn SE, Jones NP, Noronha D, Beck-Nielsen H, Viberti G; ADOPT Study Group; RECORD Steering Committee. Home PD, et al. Diabetologia. 2010 Sep;53(9):1838-45. doi: 10.1007/s00125-010-1804-y. Epub 2010 Jun 8. Diabetologia. 2010. PMID: 20532476 Free PMC article. Clinical Trial.
AIMS/HYPOTHESIS: Observational and mechanistic studies have suggested a possible relationship between treatment with metformin and decreased incidence of cancer in participants with type 2 diabetes. We extracted data for malignancies from the ADOPT (A Diabetes Outco …
AIMS/HYPOTHESIS: Observational and mechanistic studies have suggested a possible relationship between treatment with metformin and de …
Doses of insulin and its analogues and cancer occurrence in insulin-treated type 2 diabetic patients.
Mannucci E, Monami M, Balzi D, Cresci B, Pala L, Melani C, Lamanna C, Bracali I, Bigiarini M, Barchielli A, Marchionni N, Rotella CM. Mannucci E, et al. Diabetes Care. 2010 Sep;33(9):1997-2003. doi: 10.2337/dc10-0476. Epub 2010 Jun 14. Diabetes Care. 2010. PMID: 20551014 Free PMC article.

Incident cancer was associated with a dose of glargine >or=0.3 IU/kg/day even after adjusting for Charlson comorbidity score, other types of insulin administration, and metformin exposure (odds ratio 5.43 [95% CI 2.18-13.53], P < 0.001). No association between

…
Incident cancer was associated with a dose of glargine >or=0.3 IU/kg/day even after adjusting for Charlson comorbidity score, othe …
Ionizing radiation activates AMP-activated kinase (AMPK): a target for radiosensitization of human cancer cells.
Sanli T, Rashid A, Liu C, Harding S, Bristow RG, Cutz JC, Singh G, Wright J, Tsakiridis T. Sanli T, et al. Int J Radiat Oncol Biol Phys. 2010 Sep 1;78(1):221-9. doi: 10.1016/j.ijrobp.2010.03.005. Epub 2010 Jul 7. Int J Radiat Oncol Biol Phys. 2010. PMID: 20615625
We explored the regulation of AMPK by ionizing radiation (IR) and its role as a target for radiosensitization of human cancer cells. METHODS AND MATERIALS: Lung, prostate, and breast cancer cells were treated with IR (2-8 Gy) after incubation with either ATM or AMPK …
We explored the regulation of AMPK by ionizing radiation (IR) and its role as a target for radiosensitization of human cancer cells. …
New strategies in pancreatic cancer: emerging epidemiologic and therapeutic concepts.
Li D, Abbruzzese JL. Li D, et al. Clin Cancer Res. 2010 Sep 1;16(17):4313-8. doi: 10.1158/1078-0432.CCR-09-1942. Epub 2010 Jul 20. Clin Cancer Res. 2010. PMID: 20647474 Free PMC article.
Pancreatic cancer (PC) is a highly lethal disease with complex etiology involving both environmental and genetic factors. ...Experimental and epidemiologic evidence suggests that the antidiabetic drug metformin has protective antitumor activity in PC. In addition to …
Pancreatic cancer (PC) is a highly lethal disease with complex etiology involving both environmental and genetic factors. ...Experime …
Metformin: taking away the candy for cancer?
Jalving M, Gietema JA, Lefrandt JD, de Jong S, Reyners AK, Gans RO, de Vries EG. Jalving M, et al. Eur J Cancer. 2010 Sep;46(13):2369-80. doi: 10.1016/j.ejca.2010.06.012. Epub 2010 Jul 23. Eur J Cancer. 2010. PMID: 20656475 Review.
Population-based studies show that metformin treatment is associated with a dose-dependent reduction in cancer risk. The metformin treatment also increases complete pathological tumour response rates following neoadjuvant chemotherapy for breast cancer …
Population-based studies show that metformin treatment is associated with a dose-dependent reduction in cancer risk. The me …
Metformin suppresses colorectal aberrant crypt foci in a short-term clinical trial.
Hosono K, Endo H, Takahashi H, Sugiyama M, Sakai E, Uchiyama T, Suzuki K, Iida H, Sakamoto Y, Yoneda K, Koide T, Tokoro C, Abe Y, Inamori M, Nakagama H, Nakajima A. Hosono K, et al. Cancer Prev Res (Phila). 2010 Sep;3(9):1077-83. doi: 10.1158/1940-6207.CAPR-10-0186. Epub 2010 Sep 1. Cancer Prev Res (Phila). 2010. PMID: 20810669 Clinical Trial.
However, besides epidemiologic studies, little is known about the effects of metformin on human colorectal carcinogenesis. The objective of this pilot study was to evaluate the chemopreventive effect of metformin on rectal aberrant crypt foci (ACF), which are an end …
However, besides epidemiologic studies, little is known about the effects of metformin on human colorectal carcinogenesis. The object …
Metformin and other biguanides in oncology: advancing the research agenda.
Pollak M. Pollak M. Cancer Prev Res (Phila). 2010 Sep;3(9):1060-5. doi: 10.1158/1940-6207.CAPR-10-0175. Epub 2010 Sep 1. Cancer Prev Res (Phila). 2010. PMID: 20810670 Free PMC article. Review.
Retrospective studies that may be impractical to confirm prospectively suggest that diabetics treated with metformin have a substantially reduced cancer burden compared with other diabetics. It is unclear if this reflects a chemopreventive effect, an effect on trans …
Retrospective studies that may be impractical to confirm prospectively suggest that diabetics treated with metformin have a substanti …
Chemoprevention meets glucose control.
Engelman JA, Cantley LC. Engelman JA, et al. Cancer Prev Res (Phila). 2010 Sep;3(9):1049-52. doi: 10.1158/1940-6207.CAPR-10-0178. Epub 2010 Sep 1. Cancer Prev Res (Phila). 2010. PMID: 20810671
(beginning on page 1066 in this issue of the journal) assessing the efficacy of the antidiabetes drug metformin in a mouse model of lung carcinogenesis suggests protective effects via two possible avenues: Decreased circulating insulin and insulin-like growth factor levels …
(beginning on page 1066 in this issue of the journal) assessing the efficacy of the antidiabetes drug metformin in a mouse model of l …
Metformin prevents tobacco carcinogen--induced lung tumorigenesis.
Memmott RM, Mercado JR, Maier CR, Kawabata S, Fox SD, Dennis PA. Memmott RM, et al. Cancer Prev Res (Phila). 2010 Sep;3(9):1066-76. doi: 10.1158/1940-6207.CAPR-10-0055. Epub 2010 Sep 1. Cancer Prev Res (Phila). 2010. PMID: 20810672 Free PMC article.
Plasma levels of metformin were significantly higher after injection than oral administration. In liver tissue, metformin activated AMPK and inhibited mTOR. ...These studies show that metformin prevents tobacco carcinogen-induced lung tumorigenesis and suppor …
Plasma levels of metformin were significantly higher after injection than oral administration. In liver tissue, metformin acti …
[Anti-cancer activity of metformin: new perspectives for an old drug].
Beck E, Scheen AJ. Beck E, et al. Rev Med Suisse. 2010 Sep 1;6(260):1601-7. Rev Med Suisse. 2010. PMID: 20853715 Free article. Review. French.
Numerous epidemiological observational and case-control studies showed that metformin is associated with a lower incidence of cancer and a lower cancer-related death rate. ...Studies with metformin are ongoing in the field of oncology, especially as ad …
Numerous epidemiological observational and case-control studies showed that metformin is associated with a lower incidence of canc …
[Panorama of currently available treatments for patients with type 2 diabetes. The ADA/EASD treatment algorithm. Safety and tolerability].
Artola Menéndez S. Artola Menéndez S. Aten Primaria. 2010 Sep;42 Suppl 1(Suppl 1):24-32. doi: 10.1016/S0212-6567(10)70005-6. Aten Primaria. 2010. PMID: 21074073 Free PMC article. Spanish.
In general terms, clinical practice guidelines recommend starting with lifestyle modifications together with metformin, either from the outset or at 3 months; the combination should be individualized depending on the patient's profile. ...Finally, the association between i …
In general terms, clinical practice guidelines recommend starting with lifestyle modifications together with metformin, either from t …
Metformin regulates breast cancer stem cell ontogeny by transcriptional regulation of the epithelial-mesenchymal transition (EMT) status.
Vazquez-Martin A, Oliveras-Ferraros C, Cufí S, Del Barco S, Martin-Castillo B, Menendez JA. Vazquez-Martin A, et al. Cell Cycle. 2010 Sep 15;9(18):3807-14. Epub 2010 Sep 25. Cell Cycle. 2010. PMID: 20890129
Metformin treatment dynamically regulated the CD44(pos)CD24(neg/low) breast cancer stem cell immunophenotype, transcriptionally reprogrammed cells through decreased expression of key drivers of the EMT machinery including the transcription factors ZEB1, TWIST1 and S …
Metformin treatment dynamically regulated the CD44(pos)CD24(neg/low) breast cancer stem cell immunophenotype, transcriptionall …
Molecular biology of breast cancer stem cells: potential clinical applications.
Nguyen NP, Almeida FS, Chi A, Nguyen LM, Cohen D, Karlsson U, Vinh-Hung V. Nguyen NP, et al. Cancer Treat Rev. 2010 Oct;36(6):485-91. doi: 10.1016/j.ctrv.2010.02.016. Epub 2010 Mar 15. Cancer Treat Rev. 2010. PMID: 20231058 Review.
Breast cancer stem cells (CSC) have been postulated recently as responsible for failure of breast cancer treatment. ...Future clinical trials for breast cancer should include anti-cancer stem cells targeting agents in addition to conventional chemother …
Breast cancer stem cells (CSC) have been postulated recently as responsible for failure of breast cancer treatment. ...Future …
Metformin and energy metabolism in breast cancer: from insulin physiology to tumour-initiating stem cells.
Vazquez-Martin A, Oliveras-Ferraros C, Cufí S, Martin-Castillo B, Menendez JA. Vazquez-Martin A, et al. Curr Mol Med. 2010 Oct;10(7):674-91. doi: 10.2174/156652410792630625. Curr Mol Med. 2010. PMID: 20712585
A whole new area of investigation has emerged recently with regards to the anti-diabetic drug metformin and breast cancer. Metformin's anti-breast cancer actions, observed in population studies, in rodents and in cultured tumour cells, are especially e …
A whole new area of investigation has emerged recently with regards to the anti-diabetic drug metformin and breast cancer. …
Pharmacological mimicking of caloric restriction elicits epigenetic reprogramming of differentiated cells to stem-like self-renewal states.
Oliveras-Ferraros C, Vazquez-Martin A, Menendez JA. Oliveras-Ferraros C, et al. Rejuvenation Res. 2010 Oct;13(5):519-26. doi: 10.1089/rej.2010.1022. Epub 2010 Nov 3. Rejuvenation Res. 2010. PMID: 21047255
Networks of oncogenes and tumor suppressor genes that control cancer cell proliferation also regulate stem cell renewal and possibly stem cell aging. ...Cancer cell lines naturally bearing undetectable amounts of stem/progenitor-like cell populations were continuous …
Networks of oncogenes and tumor suppressor genes that control cancer cell proliferation also regulate stem cell renewal and possibly …
Teaching an old drug new tricks: metformin as a targeted therapy for lung cancer.
Antonoff MB, D'Cunha J. Antonoff MB, et al. Semin Thorac Cardiovasc Surg. 2010 Autumn;22(3):195-6. doi: 10.1053/j.semtcvs.2010.10.015. Semin Thorac Cardiovasc Surg. 2010. PMID: 21167452
In a recent article (Memmott RM, Mercado JR, Maier CR, et al: Metformin prevents tobacco carcinogen-induced lung tumorigenesis. Cancer Prev Res (Phila) 3:1066-1076, 2010), Memmott et al assessed the utility of metformin in an in vivo model of tobacco carcinog …
In a recent article (Memmott RM, Mercado JR, Maier CR, et al: Metformin prevents tobacco carcinogen-induced lung tumorigenesis. Ca …
Breast cancer and diabetes mellitus.
Schott S, Schneeweiss A, Sohn C. Schott S, et al. Exp Clin Endocrinol Diabetes. 2010 Nov;118(10):673-7. doi: 10.1055/s-0030-1254116. Epub 2010 Jun 8. Exp Clin Endocrinol Diabetes. 2010. PMID: 20533174 Review.
Up to 16% of the elderly breast cancer patients additionally suffer from diabetes. Epidemiologic studies suggest that type 2 diabetes increases breast cancer risk and goes along with an increased mortality however, there has been limited experimental evidence suppor …
Up to 16% of the elderly breast cancer patients additionally suffer from diabetes. Epidemiologic studies suggest that type 2 diabetes …
Clinical outcomes after radical prostatectomy in diabetic patients treated with metformin.
Patel T, Hruby G, Badani K, Abate-Shen C, McKiernan JM. Patel T, et al. Urology. 2010 Nov;76(5):1240-4. doi: 10.1016/j.urology.2010.03.059. Urology. 2010. PMID: 20627287
OBJECTIVES: To investigate the relationship between diabetes and metformin use with outcomes after radical prostatectomy (RP) for clinically localized cancer. ...Metformin use did not prove to be of any benefit. These observations underscore the importance fo …
OBJECTIVES: To investigate the relationship between diabetes and metformin use with outcomes after radical prostatectomy (RP) for cli …
Metformin and cancer risk in diabetic patients: a systematic review and meta-analysis.
Decensi A, Puntoni M, Goodwin P, Cazzaniga M, Gennari A, Bonanni B, Gandini S. Decensi A, et al. Cancer Prev Res (Phila). 2010 Nov;3(11):1451-61. doi: 10.1158/1940-6207.CAPR-10-0157. Epub 2010 Oct 12. Cancer Prev Res (Phila). 2010. PMID: 20947488
Metformin, an insulin-lowering agent, has been associated with decreased cancer risk in epidemiologic studies in diabetic patients. ...A trend to a dose-response relationship was noted. Metformin is associated with a decreased risk of cancer incidence …
Metformin, an insulin-lowering agent, has been associated with decreased cancer risk in epidemiologic studies in diabetic pati …
Diabetes mellitus and increased risk of cancer: focus on metformin and the insulin analogs.
McFarland MS, Cripps R. McFarland MS, et al. Pharmacotherapy. 2010 Nov;30(11):1159-78. doi: 10.1592/phco.30.11.1159. Pharmacotherapy. 2010. PMID: 20973689 Review.
Results of recently released studies documented the use of specific antidiabetic drugs with increased rates of cancer. The insulin analog glargine was the focus of four observational studies published in 2009 that outlined an increase in the rates of cancer associat …
Results of recently released studies documented the use of specific antidiabetic drugs with increased rates of cancer. The insulin an …
Metformin for aging and cancer prevention.
Anisimov VN. Anisimov VN. Aging (Albany NY). 2010 Nov;2(11):760-74. doi: 10.18632/aging.100230. Aging (Albany NY). 2010. PMID: 21084729 Free PMC article. Review.
Evidence has emerged that antidiabetic drugs are promising candidates for both life span extension and prevention of cancer. Thus, antidiabetic drugs postpone spontaneous carcinogenesis in mice and rats, as well as chemical and radiation carcinogenesis in mice, rats and ha …
Evidence has emerged that antidiabetic drugs are promising candidates for both life span extension and prevention of cancer. Thus, an …
Metformin against TGFbeta-induced epithelial-to-mesenchymal transition (EMT): from cancer stem cells to aging-associated fibrosis.
Cufí S, Vazquez-Martin A, Oliveras-Ferraros C, Martin-Castillo B, Joven J, Menendez JA. Cufí S, et al. Cell Cycle. 2010 Nov 15;9(22):4461-8. doi: 10.4161/cc.9.22.14048. Epub 2010 Nov 15. Cell Cycle. 2010. PMID: 21088486
Given that: a.) tumor-initiating cancer stem cells display a significant enrichment in the expression of basal/mesenchymal or myoepithelial markers, including an increased secretion of TGFb; b.) metformin treatment impedes the ontogeny of generating the stem cell ph …
Given that: a.) tumor-initiating cancer stem cells display a significant enrichment in the expression of basal/mesenchymal or myoepit …
Influence of comorbidities on therapeutic progression of diabetes treatment in Australian veterans: a cohort study.
Vitry AI, Roughead EE, Preiss AK, Ryan P, Ramsay EN, Gilbert AL, Caughey GE, Shakib S, Esterman A, Zhang Y, McDermott RA. Vitry AI, et al. PLoS One. 2010 Nov 17;5(11):e14024. doi: 10.1371/journal.pone.0014024. PLoS One. 2010. PMID: 21103337 Free PMC article.
METHODOLOGY/PRINCIPAL FINDINGS: A retrospective cohort study was undertaken using data from the Australian Department of Veterans' Affairs (DVA) claims database between July 2000 and June 2008. The study included new users of metformin or sulfonylurea medicines. The outcom …
METHODOLOGY/PRINCIPAL FINDINGS: A retrospective cohort study was undertaken using data from the Australian Department of Veterans' Affairs ( …
Diabetes and cancer.
Chowdhury TA. Chowdhury TA. QJM. 2010 Dec;103(12):905-15. doi: 10.1093/qjmed/hcq149. Epub 2010 Aug 25. QJM. 2010. PMID: 20739356 Free article. Review.
Diabetes and cancer are common conditions, and their co-diagnosis in the same individual is not infrequent. ...There is reasonable circumstantial evidence that metformin may decrease the risk of cancer amongst diabetic patients. Much more research is required …
Diabetes and cancer are common conditions, and their co-diagnosis in the same individual is not infrequent. ...There is reasonable ci …
Use of sulphonylurea and cancer in type 2 diabetes-The Hong Kong Diabetes Registry.
Yang X, So WY, Ma RC, Yu LW, Ko GT, Kong AP, Ng VW, Luk AO, Ozaki R, Tong PC, Chow CC, Chan JC. Yang X, et al. Diabetes Res Clin Pract. 2010 Dec;90(3):343-51. doi: 10.1016/j.diabres.2010.08.022. Diabetes Res Clin Pract. 2010. PMID: 20889221
BACKGROUND: Hyperglycaemia is a risk factor for cancer and some sulphonylureas have anti-oxidant properties. This study examined associations between use of sulphonylureas and cancer. ...After adjustment for covariates, use of gliclazide and glibenclamide was associ …
BACKGROUND: Hyperglycaemia is a risk factor for cancer and some sulphonylureas have anti-oxidant properties. This study examined asso …
[Antidiabetic therapy--a new possibility in the complex therapy of cancer?].
Bánhegyi RJ, Rus-Gal PO, Nagy AK, Martyin T, Wágner R, Varga R, Pikó B. Bánhegyi RJ, et al. Magy Onkol. 2010 Dec;54(4):315-23. doi: 10.1556/MOnkol.54.2010.4.5. Magy Onkol. 2010. PMID: 21163762 Free article. Review. Hungarian.
This makes type 2 diabetes a metabolic state favoring tumor formation, suggesting a potential application of oral insulin sensitizers in cancer therapy. Currently several international trials are testing the anti-tumor activity of metformin and thiazolidinedions (TZ …
This makes type 2 diabetes a metabolic state favoring tumor formation, suggesting a potential application of oral insulin sensitizers in …
Gender differences in metformin effect on aging, life span and spontaneous tumorigenesis in 129/Sv mice.
Anisimov VN, Piskunova TS, Popovich IG, Zabezhinski MA, Tyndyk ML, Egormin PA, Yurova MV, Rosenfeld SV, Semenchenko AV, Kovalenko IG, Poroshina TE, Berstein LM. Anisimov VN, et al. Aging (Albany NY). 2010 Dec;2(12):945-58. doi: 10.18632/aging.100245. Aging (Albany NY). 2010. PMID: 21164223 Free PMC article.
Studies in mammals have led to the suggestion that hyperglycemia and hyperinsulinemia are important factors both in aging and in the development of cancer. It is possible that the life-prolonging effects of calorie restriction are due to decreasing IGF-1 levels. ...The tre …
Studies in mammals have led to the suggestion that hyperglycemia and hyperinsulinemia are important factors both in aging and in the develop …
[Induction of ovulation].
Jacquesson L, Belaisch-Allart J, Ayel JP. Jacquesson L, et al. J Gynecol Obstet Biol Reprod (Paris). 2010 Dec;39(8 Suppl 2):S67-74. doi: 10.1016/S0368-2315(10)70032-6. J Gynecol Obstet Biol Reprod (Paris). 2010. PMID: 21185488 Free article. Review. French.
The keywords were: ovulation induction, citrate of clomiphene, gonadotropin, metformin, anti estrogens, anti aromatase, pulsatile GnRH administration, cancer, ovarian hyperstimulation, thrombosis, multiple pregnancies, and complications. ...
The keywords were: ovulation induction, citrate of clomiphene, gonadotropin, metformin, anti estrogens, anti aromatase, pulsatile GnR …
[New clinical data with metformin therapy in patients with diabetes mellitus].
Jermendy G. Jermendy G. Orv Hetil. 2010 Dec 5;151(49):2025-30. doi: 10.1556/OH.2010.29005. Orv Hetil. 2010. PMID: 21106483 Review. Hungarian.
Metformin is widely used for treating patients with type 2 diabetes mellitus. Recently, new options of metformin therapy were highlighted by several clinical observations. ...In addition, epidemiological studies unequivocally documented that metformin is asso …
Metformin is widely used for treating patients with type 2 diabetes mellitus. Recently, new options of metformin therapy were …
Metformin attenuates ovarian cancer cell growth in an AMP-kinase dispensable manner.
Rattan R, Giri S, Hartmann LC, Shridhar V. Rattan R, et al. J Cell Mol Med. 2011 Jan;15(1):166-78. doi: 10.1111/j.1582-4934.2009.00954.x. J Cell Mol Med. 2011. PMID: 19874425 Free PMC article.
Here, we report that ovarian cell lines VOSE, A2780, CP70, C200, OV202, OVCAR3, SKOV3ip, PE01 and PE04 predominantly express -alpha(1), -beta(1), -gamma(1) and -gamma(2) isoforms of AMPK subunits. Our studies show that metformin treatment (1) significantly inhibited prolif …
Here, we report that ovarian cell lines VOSE, A2780, CP70, C200, OV202, OVCAR3, SKOV3ip, PE01 and PE04 predominantly express -alpha(1), -bet …
Intensive glycaemic control and cancer risk in type 2 diabetes: a meta-analysis of major trials.
Johnson JA, Bowker SL. Johnson JA, et al. Diabetologia. 2011 Jan;54(1):25-31. doi: 10.1007/s00125-010-1933-3. Epub 2010 Oct 20. Diabetologia. 2011. PMID: 20959956
AIMS/HYPOTHESIS: The purpose of this study was to explore the relationship between hyperglycaemia in type 2 diabetes and risk of cancer incidence or cancer mortality. We were interested to determine if data from major randomised controlled trials would support a hyp …
AIMS/HYPOTHESIS: The purpose of this study was to explore the relationship between hyperglycaemia in type 2 diabetes and risk of cancer …
Metformin and cancer occurrence in insulin-treated type 2 diabetic patients.
Monami M, Colombi C, Balzi D, Dicembrini I, Giannini S, Melani C, Vitale V, Romano D, Barchielli A, Marchionni N, Rotella CM, Mannucci E. Monami M, et al. Diabetes Care. 2011 Jan;34(1):129-31. doi: 10.2337/dc10-1287. Epub 2010 Oct 27. Diabetes Care. 2011. PMID: 20980415 Free PMC article.
OBJECTIVE: Metformin is associated with reduced cancer-related morbidity and mortality. The aim of this study was to assess the effect of metformin on cancer incidence in a consecutive series of insulin-treated patients. ...CONCLUSIONS: The reduction o …
OBJECTIVE: Metformin is associated with reduced cancer-related morbidity and mortality. The aim of this study was to assess th …
Compound C induces protective autophagy in cancer cells through AMPK inhibition-independent blockade of Akt/mTOR pathway.
Vucicevic L, Misirkic M, Janjetovic K, Vilimanovich U, Sudar E, Isenovic E, Prica M, Harhaji-Trajkovic L, Kravic-Stevovic T, Bumbasirevic V, Trajkovic V. Vucicevic L, et al. Autophagy. 2011 Jan;7(1):40-50. doi: 10.4161/auto.7.1.13883. Epub 2011 Jan 1. Autophagy. 2011. PMID: 20980833
The siRNA-mediated AMPK silencing did not reduce the activity of the Akt/mTOR/p70S6K pathway and AMPK activators metformin and AIC AR failed to block compound C-induced autophagy. Autophagy inhibitors bafilomycin and chloroquine significantly increased the cytotoxicity of …
The siRNA-mediated AMPK silencing did not reduce the activity of the Akt/mTOR/p70S6K pathway and AMPK activators metformin and AIC AR …
The anti-diabetic drug metformin suppresses the metastasis-associated protein CD24 in MDA-MB-468 triple-negative breast cancer cells.
Vazquez-Martin A, Oliveras-Ferraros C, Cufí S, Del Barco S, Martin-Castillo B, Lopez-Bonet E, Menendez JA. Vazquez-Martin A, et al. Oncol Rep. 2011 Jan;25(1):135-40. Oncol Rep. 2011. PMID: 21109968
Here, we reveal that suppression of CD24 protein expression is a crucial event in the molecular mechanisms underlying the growth-inhibitory effects of the anti-diabetic drug metformin in MDA-MB-468 triple-negative (basal-like) breast cancer cells. First, we confirme …
Here, we reveal that suppression of CD24 protein expression is a crucial event in the molecular mechanisms underlying the growth-inhibitory …
Metformin and incident breast cancer among diabetic women: a population-based case-control study in Denmark.
Bosco JL, Antonsen S, Sørensen HT, Pedersen L, Lash TL. Bosco JL, et al. Cancer Epidemiol Biomarkers Prev. 2011 Jan;20(1):101-11. doi: 10.1158/1055-9965.EPI-10-0817. Epub 2010 Nov 30. Cancer Epidemiol Biomarkers Prev. 2011. PMID: 21119073
We evaluated the effect of metformin medication on the risk of incident breast cancer among peri- and postmenopausal women. ...IMPACT: This study supports the growing evidence of a role for metformin in breast cancer chemoprevention....
We evaluated the effect of metformin medication on the risk of incident breast cancer among peri- and postmenopausal women. .. …
The efficacy of dandelion root extract in inducing apoptosis in drug-resistant human melanoma cells.
Chatterjee SJ, Ovadje P, Mousa M, Hamm C, Pandey S. Chatterjee SJ, et al. Evid Based Complement Alternat Med. 2011;2011:129045. doi: 10.1155/2011/129045. Epub 2010 Dec 30. Evid Based Complement Alternat Med. 2011. PMID: 21234313 Free PMC article.
Notoriously chemoresistant melanoma has become the most prevalent form of cancer for the 25-29 North American age demographic. Standard treatment after early detection involves surgical excision (recurrence is possible), and metastatic melanoma is refractory to immuno-, ra …
Notoriously chemoresistant melanoma has become the most prevalent form of cancer for the 25-29 North American age demographic. Standa …
AMP-activated protein kinase: a cellular energy sensor with a key role in metabolic disorders and in cancer.
Hardie DG. Hardie DG. Biochem Soc Trans. 2011 Jan;39(1):1-13. doi: 10.1042/BST0390001. Biochem Soc Trans. 2011. PMID: 21265739
Because of its ability to switch cellular metabolism from anabolic to catabolic mode, AMPK has become a key drug target to combat metabolic disorders associated with overnutrition such as Type 2 diabetes, and some existing anti-diabetic drugs (e.g. metformin) and many 'nut …
Because of its ability to switch cellular metabolism from anabolic to catabolic mode, AMPK has become a key drug target to combat metabolic …
Insulin resistance: pathophysiology and rationale for treatment.
Muntoni S, Muntoni S. Muntoni S, et al. Ann Nutr Metab. 2011;58(1):25-36. doi: 10.1159/000323395. Epub 2011 Feb 8. Ann Nutr Metab. 2011. PMID: 21304221 Review.
As the preferential activation of the MAP-K pathway in insulin-resistant patients has atherogenic and mitogenic properties, this leads to atherosclerosis and cancer. Metformin may carry out direct protective action on human beta cells, inasmuch as it improves both p …
As the preferential activation of the MAP-K pathway in insulin-resistant patients has atherogenic and mitogenic properties, this leads to at …
Use of chemical genomics in assessment of the UPR.
Saito S, Tomida A. Saito S, et al. Methods Enzymol. 2011;491:327-41. doi: 10.1016/B978-0-12-385928-0.00018-3. Methods Enzymol. 2011. PMID: 21329808
We previously reported that the macrocyclic compound versipelostatin and the antidiabetic biguanides metformin, buformin, and phenformin could inhibit the UPR during glucose deprivation as well as induce the UPR by treatment of cells with 2-deoxy-d-glucose (2DG), a glycoly …
We previously reported that the macrocyclic compound versipelostatin and the antidiabetic biguanides metformin, buformin, and phenfor …
Metformin: its emerging role in oncology.
Micic D, Cvijovic G, Trajkovic V, Duntas LH, Polovina S. Micic D, et al. Hormones (Athens). 2011 Jan-Mar;10(1):5-15. doi: 10.14310/horm.2002.1288. Hormones (Athens). 2011. PMID: 21349801 Free article. Review.
Recently, several clinical studies have reported reduced incidence of neoplastic diseases in DM type 2 patients treated with metformin, as compared to diet or other antidiabetic agents. Moreover, in vitro studies have disclosed significant antiproliferative and proapoptoti …
Recently, several clinical studies have reported reduced incidence of neoplastic diseases in DM type 2 patients treated with metformin …
Pancreatogenic diabetes: special considerations for management.
Cui Y, Andersen DK. Cui Y, et al. Pancreatology. 2011;11(3):279-94. doi: 10.1159/000329188. Epub 2011 Jul 9. Pancreatology. 2011. PMID: 21757968 Review.
METHODS: Published studies on the prevalence, pathophysiology, and cancer associations of T3cDM were reviewed. The recent studies on the protective role and mechanism of metformin therapy as both an anti-diabetic and anti-neoplastic agent were reviewed, and studies …
METHODS: Published studies on the prevalence, pathophysiology, and cancer associations of T3cDM were reviewed. The recent studies on …
Antidiabetic drug metformin induces apoptosis in human MCF breast cancer via targeting ERK signaling.
Malki A, Youssef A. Malki A, et al. Oncol Res. 2011;19(6):275-85. doi: 10.3727/096504011x13021877989838. Oncol Res. 2011. PMID: 21776823
This observation led us to hypothesize that metformin might inhibit human breast cancer cells (MCF-7) growth. Here, we report that metformin induced apoptosis in human breast carcinoma cell lines MCF-7 cells via novel signaling pathway. ...This pathway has no …
This observation led us to hypothesize that metformin might inhibit human breast cancer cells (MCF-7) growth. Here, we report …
Metformin as an energy restriction mimetic agent for breast cancer prevention.
Zhu Z, Jiang W, Thompson MD, McGinley JN, Thompson HJ. Zhu Z, et al. J Carcinog. 2011;10:17. doi: 10.4103/1477-3163.83043. Epub 2011 Jul 19. J Carcinog. 2011. PMID: 21799661 Free PMC article.
Human breast cancer cell growth inhibition in response to metformin was only observed at high concentrations. ...However, metformin may be an effective component of multiagent interventions that target cancer-initiated cells. ...
Human breast cancer cell growth inhibition in response to metformin was only observed at high concentrations. ...However, m …
Metformin induces apoptosis of lung cancer cells through activating JNK/p38 MAPK pathway and GADD153.
Wu N, Gu C, Gu H, Hu H, Han Y, Li Q. Wu N, et al. Neoplasma. 2011;58(6):482-90. doi: 10.4149/neo_2011_06_482. Neoplasma. 2011. PMID: 21895401
However, the underlying molecular mechanisms for its anti-neoplastic activity has not been yet clarified and the effect of metformin on human lung cancer remains unknown. In this study we revealed for the first time that metformin treatment led to increased a …
However, the underlying molecular mechanisms for its anti-neoplastic activity has not been yet clarified and the effect of metformin …
Adenosine monophosphate-activated protein kinase: a central regulator of metabolism with roles in diabetes, cancer, and viral infection.
Hardie DG. Hardie DG. Cold Spring Harb Symp Quant Biol. 2011;76:155-64. doi: 10.1101/sqb.2011.76.010819. Epub 2011 Nov 9. Cold Spring Harb Symp Quant Biol. 2011. PMID: 22071265 Review.
AMPK is activated by the antidiabetic drug metformin, and by many natural products including "nutraceuticals" and compounds used in traditional medicines. ...
AMPK is activated by the antidiabetic drug metformin, and by many natural products including "nutraceuticals" and compounds used in t …
Obesity, inflammation, and postmenopausal breast cancer: therapeutic implications.
Macciò A, Madeddu C. Macciò A, et al. ScientificWorldJournal. 2011;11:2020-36. doi: 10.1100/2011/806787. Epub 2011 Oct 27. ScientificWorldJournal. 2011. PMID: 22125453 Free PMC article. Review.
Breast cancer is the female malignant neoplasia with the highest incidence in the industrialized world. ...Weight increase and obesity have been identified as the most important risk and prognostic factors for breast cancer in postmenopausal women. Several hypothese …
Breast cancer is the female malignant neoplasia with the highest incidence in the industrialized world. ...Weight increase and obesit …
Metformin represses self-renewal of the human breast carcinoma stem cells via inhibition of estrogen receptor-mediated OCT4 expression.
Jung JW, Park SB, Lee SJ, Seo MS, Trosko JE, Kang KS. Jung JW, et al. PLoS One. 2011;6(11):e28068. doi: 10.1371/journal.pone.0028068. Epub 2011 Nov 23. PLoS One. 2011. PMID: 22132214 Free PMC article.
Metformin, a Type II diabetic treatment drug, which inhibits transcription of gluconeogenesis genes, has recently been shown to lower the risk of some diabetes-related tumors, including breast cancer. ...To test the hypothesis that metformin might be reducing …
Metformin, a Type II diabetic treatment drug, which inhibits transcription of gluconeogenesis genes, has recently been shown to lower …
Use of Metformin in Patients with Kidney and Cardiovascular Diseases.
Klachko D, Whaley-Connell A. Klachko D, et al. Cardiorenal Med. 2011;1(2):87-95. doi: 10.1159/000327151. Epub 2011 Apr 14. Cardiorenal Med. 2011. PMID: 22294985 Free PMC article.
The efficacy of metformin in reducing hyperglycemia is well established, and there is emerging evidence that its chronic use is associated with cancer and cardiovascular disease (CVD) risk reduction. While the hypoglycemic properties of metformin are largely …
The efficacy of metformin in reducing hyperglycemia is well established, and there is emerging evidence that its chronic use is assoc …
[Effectiveness of aromatase inhibitors in comparison with metformin for neoadjuvant treatment in patients with endometrial cancer].
Bershteĭn LM, Maksimov SIa, Danilova MA, Gershfel'd ÉD, Boiarkina MP, Khadzhimba AS, Kovalevskiĭ AIu, Turkevich EA, Meshkova IE. Bershteĭn LM, et al. Vopr Onkol. 2011;57(6):737-41. Vopr Onkol. 2011. PMID: 22416390 Russian.
We compared the efficacy of endometrial cancer neoadjuvant treatment in 38 patients receiving nonsteroid (letrozol, anastrozol) or steroid (ekzemestan) aromatase inhibitors and 12 patients receiving metformin. The changes in glucose metabolism were revealed in 26.3% …
We compared the efficacy of endometrial cancer neoadjuvant treatment in 38 patients receiving nonsteroid (letrozol, anastrozol) or st …
Progesterone for Symptomatic Perimenopause Treatment - Progesterone politics, physiology and potential for perimenopause.
Prior JC. Prior JC. Facts Views Vis Obgyn. 2011;3(2):109-20. Facts Views Vis Obgyn. 2011. PMID: 24753856 Free PMC article.
Menorrhagia is treated with ibuprofen 200mg/6h plus OMP4 cycle d 4-28. For insulin resistance, metformin plus cyclic or daily OMP4 decreases insulin resistance and weight gain. Non-responsive migraines need daily OMP4 plus usual therapies. ...In summary, OMP4 is a physiolo …
Menorrhagia is treated with ibuprofen 200mg/6h plus OMP4 cycle d 4-28. For insulin resistance, metformin plus cyclic or daily OMP4 de …
5,123 results